PMCID	SENTENCE_NUMBER	SENTENCE	SENTENCE_INDICES	ONTOLOGY_CONCEPT_IDS_LIST
16279840	0	['Persistent Amyloidosis following Suppression of Aβ Production in a Transgenic Model of Alzheimer Disease\n\nAbstract\n\nBackground\n\nThe proteases (secretases) that cleave amyloid-β (Aβ) peptide from the amyloid precursor protein (APP) have been the focus of considerable investigation in the development of treatments for Alzheimer disease.']	(0, 336)	['GO:0034205', 'GO:0034205', 'MOP:0000780', 'PR:000004168', 'PR:000004168', 'PR:000004168', 'PR:000004168']
16279840	1	['The prediction has been that reducing Aβ production in the brain, even after the onset of clinical symptoms and the development of associated pathology, will facilitate the repair of damaged tissue and removal of amyloid lesions.']	(337, 566)	['CHEBI:60425', 'GO:0034205', 'GO:0034205', 'UBERON:0000955', 'UBERON:0000479']
16279840	2	['However, no long-term studies using animal models of amyloid pathology have yet been performed to test this hypothesis.']	(567, 686)	['CHEBI:60425', 'NCBITaxon:33208']
16279840	3	['Methods and Findings\n\nWe have generated a transgenic mouse model that genetically mimics the arrest of Aβ production expected from treatment with secretase inhibitors.']	(688, 855)	['CHEBI:35222', 'GO:0034205', 'GO:0034205', 'NCBITaxon:10088', 'SO:0000704']
16279840	4	['These mice overexpress mutant APP from a vector that can be regulated by doxycycline.']	(856, 941)	['CHEBI:50845', 'GO:0010467', 'GO:0065007', 'NCBITaxon:10088', 'PR:000004168', 'SO:0000440']
16279840	5	['Under normal conditions, high-level expression of APP quickly induces fulminant amyloid pathology.']	(942, 1040)	['CHEBI:60425', 'GO:0010467', 'PR:000004168']
16279840	6	['We show that doxycycline administration inhibits transgenic APP expression by greater than 95% and reduces Aβ production to levels found in nontransgenic mice.']	(1041, 1200)	['CHEBI:50845', 'GO:0010467', 'GO:0034205', 'GO:0034205', 'NCBITaxon:10088', 'PR:000004168']
16279840	7	['Suppression of transgenic Aβ synthesis in this model abruptly halts the progression of amyloid pathology.']	(1201, 1306)	['CHEBI:60425', 'GO:0034205', 'GO:0034205']
16279840	8	['However, formation and disaggregation of amyloid deposits appear to be in disequilibrium as the plaques require far longer to disperse than to assemble.']	(1307, 1459)	['CHEBI:60425']
16279840	9	['Mice in which APP synthesis was suppressed for as long as 6 mo after the formation of Aβ deposits retain a considerable amyloid load, with little sign of active clearance.']	(1460, 1631)	['CHEBI:60425', 'GO:0042983', 'GO:0042983', 'NCBITaxon:10088', 'PR:000004168']
16279840	10	['Conclusion\n\nThis study demonstrates that amyloid lesions in transgenic mice are highly stable structures in vivo that are slow to disaggregate.']	(1633, 1776)	['CHEBI:60425', 'NCBITaxon:10088']
16279840	11	['Our findings suggest that arresting Aβ production in patients with Alzheimer disease should halt the progression of pathology, but that early treatment may be imperative, as it appears that amyloid deposits, once formed, will require additional intervention to clear.']	(1777, 2044)	['CHEBI:60425', 'GO:0034205', 'GO:0034205']
16279840	12	['Introduction\n\nOver a decade ago the amyloid cascade hypothesis predicted that increased levels of amyloid-β (Aβ) peptide lead to secondary pathologies that ultimately culminate in the onset of Alzheimer disease (AD) [1].']	(2046, 2266)	['CHEBI:60425']
16279840	13	['Early support for this hypothesis came from genetic studies linking early-onset AD to mutations in the amyloid precursor protein (APP), from which Aβ is derived, and presenilins 1 and 2, which are interchangeable components of a endoprotease complex that releases Aβ from APP (for review see [2,3]).']	(2267, 2566)	['GO:0032991', 'PR:000004168', 'PR:000004168', 'PR:000004168', 'PR:000004168', 'PR:000013344', 'PR:000013345', 'PR:000013344', 'PR:000013345', 'PR:000004168', 'SO:0000704']
16279840	14	['If, as predicted, overproduction of Aβ initiates the cascade of events leading to disease, then therapeutic strategies that lower Aβ levels should either arrest or reverse the progression from peptide to dementia.']	(2567, 2780)	['GO:0034205', 'GO:0034205', 'GO:0034205']
16279840	15	['Early evidence from clinical trials of antibody-mediated clearance, one of the first Aβ-lowering approaches tested in humans, suggested that treatments designed to reduce amyloid burden may indeed be beneficial.']	(2782, 2993)	['CHEBI:60425', 'GO:0042571', 'NCBITaxon:9606']
16279840	16	["Although the trials were halted because of adverse effects in a subset of volunteers [4,5], further analysis of several patients found evidence that amyloid pathology, and to a lesser degree cognitive function, was improved in proportion to the patient's titer of Aβ-specific antibody [6,7]."]	(2994, 3285)	['CHEBI:60425', 'GO:0050890', 'GO:0042571']
16279840	17	['While this approach is promising, constant exposure to antibodies that recognize an epitope highly enriched in the brain may have unexpected side effects that will limit its long-term use.']	(3286, 3474)	['GO:0042571', 'UBERON:0000955']
16279840	18	['An alternative approach that is being actively pursued for future treatment of AD seeks to lower Aβ levels by limiting its production from the precursor protein APP.']	(3476, 3641)	['PR:000004168']
16279840	19	['Peptide Aβ is released from APP by the action of two enzymes, the β-APP cleaving enzyme 1 (BACE1) and γ-secretase, which cleave the holoprotein at the N- and C-termini of Aβ, respectively.']	(3642, 3830)	['CHEBI:33837', 'GO:0070765', 'GO:0070765', 'GO:0070765', 'MOP:0000780', 'MOP:0000780', 'PR:000004168', 'PR:000004615', 'PR:000004615', 'PR:000004615', 'PR:000004615', 'PR:000004615', 'PR:000004615', 'PR:000004615']
16279840	20	['Several inhibitors of γ-secretase have already been produced [8,9], and small molecule inhibitors of β-APP cleaving enzyme 1 are currently being developed [10,11].']	(3831, 3994)	['CHEBI:35222', 'CHEBI:36357', 'CHEBI:35222', 'GO:0070765', 'GO:0070765', 'GO:0070765', 'MOP:0000780', 'PR:000004615', 'PR:000004615', 'PR:000004615', 'PR:000004615', 'PR:000004615', 'PR:000004615']
16279840	21	['The long-term effectiveness of this approach in either humans or model systems, however, has not been reported.']	(3995, 4106)	['NCBITaxon:9606']
16279840	22	['Although loss of β-APP cleaving enzyme 1 function can prevent the development of plaques in transgenic mouse models for AD (F. Laird, H. Cai, P. C. Wong, personal communication), it is not known whether the brain can clear pre-existing amyloid deposits once production of Aβ has been suppressed.']	(4107, 4402)	['CHEBI:60425', 'GO:0034205', 'GO:0034205', 'GO:0034205', 'MOP:0000780', 'NCBITaxon:10088', 'PR:000004615', 'PR:000004615', 'PR:000004615', 'PR:000004615', 'PR:000004615', 'PR:000004615', 'UBERON:0000955']
16279840	23	['Clearly, the amyloid-lowering approach should be rigorously examined in animal models before these reagents are tested in patients.']	(4404, 4535)	['CHEBI:60425', 'CHEBI:33893', 'NCBITaxon:33208']
16279840	24	['However, the chemical secretase inhibitors most likely to reach human trials are still in development.']	(4536, 4638)	['CHEBI:35222', 'NCBITaxon:9606']
16279840	25	['Therefore, we developed a mouse model of Alzheimer-type amyloid that expresses a controllable APP transgene.']	(4639, 4747)	['CHEBI:60425', 'GO:0010467', 'GO:0065007', 'NCBITaxon:10088', 'PR:000004168', 'SO:0000902']
16279840	26	['This system, commonly known as the tet-off system, can be regulated by analogs of tetracycline administered in food or water [12,13].']	(4748, 4881)	['CHEBI:27902', 'CHEBI:33290', 'CHEBI:15377', 'GO:0065007']
16279840	27	['The strong expression levels produced with the tet-off vectors, combined with the ability to reduce this expression by several orders of magnitude with tetracycline [14], allowed for a stringent test of how a highly effective pharmaceutical inhibitor of Aβ production would impact the progression of amyloid pathology and whether reversal of these lesions might be possible following such treatment.']	(4882, 5281)	['CHEBI:27902', 'CHEBI:52217', 'CHEBI:35222', 'CHEBI:60425', 'GO:0010467', 'GO:0010467', 'GO:0034205', 'GO:0034205', 'SO:0000440']
16279840	28	['Methods\n\nTransgene Construction\n\nWe created a tetracycline-responsive chimeric mouse/human APP695Swedish/Indiana (swe/ind) vector by replacing the promoter region of the moPrP.XhoI vector (also known as pPrPpE1/E2,3sal [15]) with the tetracycline-responsive promoter of pTetSplice (Life Technologies, Rockville, Maryland, United States), and then ligating mouse APP with a humanized Aβ domain (mo/huAPP695) cDNA into the new vector.']	(5283, 5715)	['CHEBI:27902', 'CHEBI:27902', 'GO:0006266', 'NCBITaxon:10088', 'NCBITaxon:9606', 'NCBITaxon:10088', 'NCBITaxon:10088', 'PR:P04925', 'PR:000004168', 'SO:0000902', 'SO:0000440', 'SO:0000167', 'SO:0000167', 'SO:0000440', 'SO:0000167', 'SO:0000417', 'SO:0000440']
16279840	29	['We began by cloning the tetracycline-responsive promoter (bp 6–481) from pTetSplice by PCR using primers that added external BamHI and NotI sites to the 5′ end and a BamHI site to the 3′ end, while destroying XhoI and BamHI sites within the promoter (forward: GCC GGA TCC GCG GCC GCC GTC GAG TTT ACC ACT CCC TAT C; reverse: GCC GGA TCC ACT CTA GAA GAT CCC CGG GTA CCG).']	(5716, 6085)	['CHEBI:27902', 'PR:P23940', 'PR:P23940', 'PR:P23940', 'SO:0000167', 'SO:0000028', 'SO:0000112', 'SO:0000167', 'SO:0001030', 'SO:0001031']
16279840	30	['We then isolated the moPrP.XhoI intron by amplification with primers that added an external BamHI site to the 5′ end of exon 1 and ran through the Asp718 site of exon 2 (forward: GCC GGA TCC GAT CAG CAG ACC GAT TCT GG; reverse: GCC GGT ACC ACT AGG AAG GCA GAA TGC).']	(6086, 6351)	['PR:P04925', 'PR:P23940', 'SO:0000188', 'SO:0000112', 'SO:0000147', 'SO:0000147', 'SO:0001030', 'SO:0001031']
16279840	31	['This 2-kb intron fragment was cloned into a TA cloning vector (Invitrogen, Carlsbad, California, United States), then excised by Asp718 digestion and ligated to the 6.8-kb Asp718 fragment of moPrP.XhoI containing exon 2, exon 3, the 3′ UTR, and pBluescript to generate an intermediate vector with all three exons and a central intron but no promoter.']	(6352, 6702)	['GO:0006266', 'PR:P04925', 'SO:0000188', 'SO:0000440', 'SO:0000147', 'SO:0000147', 'SO:0000205', 'SO:0000205', 'SO:0000205', 'SO:0000440', 'SO:0000147', 'SO:0000188', 'SO:0000167']
16279840	32	['This vector was then opened at the BamHI site introduced by the intron cloning primer, and ligated to the 0.5-kb BamHI-cut tetracycline promoter fragment.']	(6703, 6857)	['CHEBI:27902', 'GO:0006266', 'MOP:0000780', 'PR:P23940', 'PR:P23940', 'SO:0000440', 'SO:0000188', 'SO:0000112', 'SO:0000167']
16279840	33	['This ligation generated a 9.3-kb vector encoding the tetracycline promoter from pTetSplice with two exons, one intron, and the original 3′ UTR of the moPrP.XhoI vector, all carried in the pBluescript cloning vector.']	(6858, 7073)	['CHEBI:27902', 'GO:0006266', 'PR:P04925', 'SO:0000440', 'SO:0000167', 'SO:0000147', 'SO:0000188', 'SO:0000205', 'SO:0000205', 'SO:0000205', 'SO:0000440', 'SO:0000440']
16279840	34	['We incorporated the Swedish (KM570/571NL) and Indiana (V617F) mutations into the mo/huAPP695 cDNA (in BS-KS) by PCR using a four-primer strategy: first, two partially overlapping products were generated in separate reactions using primers that encode the desired mutations (Swedish forward: GGA GAT CTC TGA AGT GAA TCT GGA TGC AGA ATT CCG/Indiana reverse: GGG TGA TGA AAA TCA CGG TTG C; Indiana forward: CAA CCG TGA TTT TCA TCA CCC TGG/M13 reverse).']	(7075, 7524)	['NCBITaxon:10088', 'SO:0000112', 'SO:0000112', 'SO:0001030', 'SO:0001031', 'SO:0001030', 'SO:0001031']
16279840	35	['The two PCR products were ligated, digested with BglII and ApaI and cloned back into the original mo/huAPP695-BS-KS vector.']	(7525, 7648)	['GO:0006266', 'NCBITaxon:10088', 'SO:0000006', 'SO:0000006', 'SO:0000440']
16279840	36	['Finally, the new APP695swe/ind was subcloned into the XhoI site of the moPrP-tetP vector from above to complete the construct.']	(7649, 7775)	['PR:P04925', 'SO:0000440']
16279840	37	['Pronuclear Injection, Screening of Founders, and Maintenance of the Lines\n\nThe moPrP-tetP-mo/huAPP695swe/ind vector was linearized and the pBluescript domain excised by digestion with NotI.']	(7777, 7966)	['GO:0045120', 'NCBITaxon:10088', 'PR:P04925', 'SO:0000440']
16279840	38	['The purified vector was injected into the pronucleus of fertilized eggs from C57BL/6J × C3HeJ F1 matings.']	(7967, 8072)	['CL:0000025', 'GO:0009566', 'GO:0007618', 'GO:0045120', 'SO:0000440']
16279840	39	['Founder animals were screened for the presence of the transgene by three-way PCR using the S36 and PrP-S/PrP-AS primers described below.']	(8073, 8209)	['NCBITaxon:33208', 'PR:000001886', 'PR:000001886', 'SO:0000902', 'SO:0000112']
16279840	40	['Transgene-positive founders were bred to animals expressing the tetracycline transactivator (tTA) under control of the calcium-calmodulin kinase IIα (CaMKIIα) promoter obtained from Jackson Laboratory [16] (Bar Harbor, Maine, United States; stock # 3010; B6;CBA-TgN[Camk2a-tTA]1Mmay).']	(8210, 8494)	['CHEBI:27902', 'GO:0010467', 'GO:0065007', 'NCBITaxon:33208', 'PR:000003199', 'PR:000003199', 'PR:000003199', 'PR:000003199', 'PR:000003199', 'PR:000003199', 'PR:000003199', 'SO:0000902', 'SO:0000167']
16279840	41	['The colony was thereafter maintained by crossing single transgenic tTA and APP offspring for each of the four APP lines.']	(8495, 8615)	['PR:000004168', 'PR:000004168']
16279840	42	['All mice were provided fresh food and water ad libitum.']	(8616, 8671)	['CHEBI:33290', 'CHEBI:15377', 'NCBITaxon:10088']
16279840	43	['Animal protocols were approved by both the Johns Hopkins University and the California Institute of Technology Institutional Animal Care and Use Committees.']	(8672, 8828)	['NCBITaxon:33208', 'NCBITaxon:33208']
16279840	44	['Doxycycline Administration\n\nDoxycycline (dox) was administered through commercially available dox-containing chow (BioServ, Frenchtown, New Jersey, United States).']	(8830, 8993)	['CHEBI:50845', 'CHEBI:50845', 'CHEBI:50845', 'CHEBI:50845', 'CHEBI:33290']
16279840	45	['The chow contained 200 mg/kg of antibiotic; based on estimated consumption of 5 g per mouse per day, the expected dose to each animal was 1 mg dox per day.']	(8994, 9149)	['CHEBI:33290', 'CHEBI:33282', 'CHEBI:50845', 'GO:0007631', 'NCBITaxon:10088', 'NCBITaxon:33208']
16279840	46	['The average 25-g animal therefore received 40 μg of dox per gram body weight per day.']	(9150, 9235)	['CHEBI:50845', 'NCBITaxon:33208']
16279840	47	['Chow was changed 1–2 times per week to prevent breakdown of the antibiotic.']	(9236, 9311)	['CHEBI:33290', 'CHEBI:33282', 'GO:0017001', 'GO:0017001', 'GO:0017001']
16279840	48	['Genotyping\n\nOffspring were genotyped for the presence of each transgene by PCR amplification of genomic DNA extracted from a 5-mm tail biopsy.']	(9313, 9455)	['GO:0006277', 'GO:0006277', 'GO:0006277', 'SO:0000902', 'SO:0001026', 'UBERON:0002415']
16279840	49	['Tails were heated to 95 °C for 45 min in 250 μl of 50 mM NaOH, vortexed, then neutralized with an equal volume of 0.5 M Tris-HCl (pH 5.5).']	(9456, 9594)	['CHEBI:32145', 'CHEBI:9754', 'CHEBI:17883', 'UBERON:0002415']
16279840	50	['Debris was sedimented by centrifugation, and 3 μl of supernatant was used for amplification.']	(9595, 9687)	[]
16279840	51	['Genotyping for APP and tTA transgenes was performed in the same PCR reaction, using five separate primers.']	(9689, 9795)	['PR:000004168', 'SO:0000902', 'SO:0000112']
16279840	52	['APP was amplified using forward primer S36 located in the 3′ end of the APP cDNA (CCG AGA TCT CTG AAG TGA AGA TGG ATG) and reverse primer PrP-AS-J located in the 3′ UTR of the vector (CCA AGC CTA GAC CAC GAG AAT GC).']	(9796, 10012)	['PR:000004168', 'PR:000004168', 'PR:000001886', 'SO:0000121', 'SO:0000121', 'SO:0000132', 'SO:0000132', 'SO:0000205', 'SO:0000205', 'SO:0000205', 'SO:0000440']
16279840	53	['The tTA transgene was detected using a primer set that amplified across its two subdomains with tet forward located within the Tn10 tetracycline repressor (CGC TGT GGG GCA TTT TAC TTT AG) and tet reverse within the HSV1 VP16 (CAT GTC CAG ATC GAA ATC GTC).']	(10013, 10268)	['CHEBI:27902', 'NCBITaxon:10298', 'PR:P04483', 'PR:P06492', 'SO:0000902', 'SO:0000112', 'SO:0001030', 'SO:0001031']
16279840	54	['All reactions, whether transgene-positive or not, amplified a segment of the endogenous prion protein gene as a control for DNA quality using a forward primer, PrP-S-J, specific to the mouse PrP open reading frame (GGG ACT ATG TGG ACT GAT GTC GG) and a reverse primer, PrP-AS-J, shared by the 3′ UTR of the endogenous PrP gene and the transgene vector.']	(10269, 10621)	['NCBITaxon:10088', 'PR:000001886', 'PR:000001886', 'PR:000001886', 'PR:000001886', 'PR:000001886', 'PR:000001886', 'SO:0000902', 'SO:0000842', 'SO:0000842', 'SO:0000842', 'SO:0000121', 'SO:0000121', 'SO:0000236', 'SO:0000236', 'SO:0000236', 'SO:0000132', 'SO:0000132', 'SO:0000205', 'SO:0000205', 'SO:0000205', 'SO:0000704', 'SO:0000902', 'SO:0000440']
16279840	55	['Amplification reactions were run for 37 cycles at 94 °C for 30 s, 64 °C for 1 min, and 72 °C for 1 min.']	(10622, 10725)	[]
16279840	56	['All samples, transgenic and wild-type, gave a 750-bp product from the endogenous PrP gene.']	(10726, 10816)	['PR:000001886', 'SO:0000028', 'SO:0000704']
16279840	57	['The APP transgene yielded an additional band at 400 bp; the tTA product fell in between at 480 bp.']	(10817, 10915)	['PR:000004168', 'SO:0000902', 'SO:0000028', 'SO:0000028']
16279840	58	['Immunoblotting/Quantitation\n\nFrozen cortical or whole forebrain tissue was homogenized by sonication in five volumes of phosphate-buffered saline (PBS) with 5 mM EDTA and protease inhibitors (Mammalian cell cocktail, Sigma, St. Louis, Missouri, United States), using a probe sonicator set to 50% output (TEKMAR, Cincinnati, Ohio, United States).']	(10917, 11262)	['CHEBI:60004', 'NCBITaxon:40674', 'UBERON:0001851', 'UBERON:0001890', 'UBERON:0000479']
16279840	59	['After dilution with an equal volume of PBS/EDTA/protease inhibitor, the samples were centrifuged briefly and the supernatant used for analysis.']	(11263, 11406)	[]
16279840	60	['Fifty micrograms (6E10 and CT15) or 5 μg (22C11) of brain homogenate was loaded per lane onto 7.5%, 10%–20%, or 4%–20% Tris-HCl PAGE gels (Bio-Rad Laboratories, Hercules, California, United States) and electrophoresed for several hours in 1× Tris-glycine–sodium dodecyl sulfate (1×TG-SDS) buffer (6E10 and 22C11; Amresco, Solon, Ohio, United States) or 1× Tris-tricine-SDS buffer (CT15; Invitrogen, Carlsbad, California, United States).']	(11407, 11843)	['CHEBI:9754', 'CHEBI:17883', 'CHEBI:9754', 'CHEBI:8984', 'CHEBI:8984', 'CHEBI:8984', 'CHEBI:8984', 'CHEBI:9754', 'CHEBI:46760', 'CHEBI:8984', 'UBERON:0000955']
16279840	61	['Proteins were transferred overnight to 0.45-μm Optitran nitrocellulose (Schleicher and Schuell, Keene, New Hampshire, United States) in 1× TG buffer (Amresco).']	(11844, 12003)	['CHEBI:53325']
16279840	62	['Blots were blocked in PBS containing 5% nonfat dry milk powder, and incubated for 3 h at room temperature in blocking solution with one of the following antibodies: mouse monoclonal 22C11 (kind gift of Konrad Beyreuther and Andreas Weidemann; [17]) diluted 1:1,000, mouse monoclonal 6E10 (Signet Laboratories, Dedham, Massachusetts, United States) diluted 1:2,500, rabbit polyclonal anti-superoxide dismutase 1 (m/hSOD1) [18] diluted 1:2,500 to 1:4,000, or rabbit polyclonal CT15 (kind gift of Ed Koo; [19]) diluted 1:1,000.']	(12004, 12528)	['CHEBI:75958', 'CHEBI:18421', 'GO:0042571', 'NCBITaxon:10088', 'NCBITaxon:10088', 'NCBITaxon:9986', 'NCBITaxon:9986', 'PR:000015399', 'PR:000015399', 'PR:000015399', 'PR:P00441', 'UBERON:0001913']
16279840	63	['Subsequently, the blots were washed with PBS containing 0.1% Tween-20, and then incubated with either goat anti-mouse– or goat anti-rabbit–HRP conjugated secondary antibody diluted 1:1,000 in blocking solution.']	(12529, 12739)	['CHEBI:53424', 'CHEBI:53424', 'CHEBI:53424', 'CHEBI:75958', 'GO:0042571', 'MOP:0000779', 'NCBITaxon:9925', 'NCBITaxon:10088', 'NCBITaxon:9925', 'NCBITaxon:9986']
16279840	64	['After several additional rinses in PBS with 0.1% Tween-20, blots were developed with enhanced chemiluminescence reagent and imaged with the Bio-Rad Molecular Imager FX system.']	(12740, 12915)	['CHEBI:53424', 'CHEBI:53424', 'CHEBI:53424', 'CHEBI:33893']
16279840	65	['Staining intensity within each lane was quantified using the Quantity One image analysis software (Molecular Imager FX, Bio-Rad Laboratories).']	(12917, 13059)	[]
16279840	66	['Background was calculated from across the image and subtracted from the entire file.']	(13060, 13144)	[]
16279840	67	['The signal intensity for each band (corrected signal intensity × pixel number) was then calculated using the Volume report tool.']	(13145, 13273)	[]
16279840	68	['Slot Blot mRNA Analysis\n\nFive micrograms per sample of total RNA extracted from fresh-frozen brain, liver, kidney, heart, lung, spleen, and skeletal muscle was vacuum-filtered through 0.45-μm Optitran nitrocellulose.']	(13275, 13491)	['CHEBI:53325', 'UBERON:0000955', 'UBERON:0002107', 'UBERON:0002113', 'UBERON:0000948', 'UBERON:0002048', 'UBERON:0002106', 'UBERON:0004288']
16279840	69	['After several washes through the manifold with 10× SSC, blots were UV-cross-linked and probed with a radiolabeled ∼350-bp BglII–XhoI cDNA fragment of mo/huAPP695 cDNA.']	(13492, 13659)	['MOP:0000779', 'NCBITaxon:10088', 'SO:0000028']
16279840	70	['After hybridizing overnight at 65 °C in 1% BSA/1 mM EDTA/0.5 M sodium phosphate buffer (pH 7.2)/7% SDS [20], the blots were washed twice at 65 °C for 30 min each in 0.1% BSA/1 mM EDTA/40 mM sodium phosphate buffer (pH 7.2)/5% SDS before two final 30-min washes at 65 °C with 1 mM EDTA/40 mM sodium phosphate buffer (pH 7.2)/1% SDS.']	(13660, 13991)	['CHEBI:37586', 'CHEBI:37586', 'CHEBI:8984', 'CHEBI:37586', 'CHEBI:37586', 'CHEBI:8984', 'CHEBI:37586', 'CHEBI:37586', 'CHEBI:8984', 'GO:0097617']
16279840	71	['Blots were wrapped wet and exposed to phosphorscreens overnight at room temperature.']	(13992, 14076)	[]
16279840	72	['Amyloid Histology\n\nMice were euthanized by ether inhalation and brains removed for immersion fixation in 4% paraformaldehyde/1× PBS.']	(14078, 14210)	['CHEBI:60425', 'CHEBI:25698', 'NCBITaxon:10088', 'UBERON:0000955']
16279840	73	['After 48 h in fixative at 4 °C, brains were transferred to PBS, dehydrated in alcohols, treated with cedarwood oil and methylsalicylate, and embedded in paraffin for sectioning.']	(14211, 14388)	['CHEBI:50913', 'CHEBI:30879', 'CHEBI:31832', 'UBERON:0000955']
16279840	74	["Hirano silver stain\n\nSilver impregnation histology was performed on 10-μm paraffin-embedded sections by Hirano's modification of the Bielschowsky method [21]."]	(14390, 14548)	[]
16279840	75	['Briefly, sections were deparaffinized through xylene and alcohols into tap water before being placed into fresh 20% silver nitrate solution for 20 min.']	(14549, 14700)	['CHEBI:27338', 'CHEBI:30879', 'CHEBI:15377', 'CHEBI:32130', 'CHEBI:32130', 'CHEBI:75958']
16279840	76	['After being washed thoroughly with distilled water, slides were immersed in 20% silver nitrate solution titrated with fresh ammonium hydroxide.']	(14701, 14844)	['CHEBI:15377', 'CHEBI:32130', 'CHEBI:32130', 'CHEBI:75958', 'CHEBI:18219', 'CHEBI:18219']
16279840	77	['After 20 min, slides were washed with ammonia water before being individually developed with 100 μl of developer (20 ml of 37% formaldehyde, 100 ml of distilled water, 50 μl of concentrated nitric acid, and 0.5 g of citric acid) added to 50 ml of titrated silver nitrate solution.']	(14845, 15125)	['CHEBI:18219', 'CHEBI:18219', 'CHEBI:16842', 'CHEBI:15377', 'CHEBI:48107', 'CHEBI:48107', 'CHEBI:30769', 'CHEBI:30769', 'CHEBI:32130', 'CHEBI:32130', 'CHEBI:75958']
16279840	78	['Slides were then rinsed in tap water, fixed in 5% sodium thiosulfate, and dehydrated through alcohols and xylene.']	(15126, 15239)	['CHEBI:15377', 'CHEBI:30879', 'CHEBI:27338']
16279840	79	['Thioflavin-S staining\n\nFollowing deparaffinization of sections through xylene and alcohols, amyloid impregnation with thioflavin-S was performed according to the Guntern modification of the standard protocol.']	(15241, 15449)	['CHEBI:27338', 'CHEBI:30879', 'CHEBI:60425']
16279840	80	['Slides holding 10-μm paraffin sections were washed twice in distilled water, then immersed for 5 min in a 0.25% potassium permanganate solution, followed by 5 min in a 1% potassium metabisulfate/1% oxalic acid solution.']	(15450, 15669)	['CHEBI:15377', 'CHEBI:75958', 'CHEBI:16995', 'CHEBI:16995', 'CHEBI:75958']
16279840	81	['After this preparation, slides were placed into a filtered aqueous 0.02% thioflavin-S solution (Chroma-Gesellschaft Schmid, Kongen, Germany) for 8 min.']	(15670, 15821)	['CHEBI:15377', 'CHEBI:75958']
16279840	82	['Excess stain was removed by two brief rinses in 80% ethanol, then two in distilled water, after which slides were finished in aqueous mounting medium for florescence photomicrography.']	(15822, 16005)	['CHEBI:16236', 'CHEBI:15377', 'CHEBI:15377']
16279840	83	['Ubiquitin, glial fibrillary acidic protein, and Aβ immunohistochemistry\n\nPrior to immunostaining, slides were deparaffinized by oven heating followed by immersion in xylene.']	(16007, 16180)	['CHEBI:37527', 'CHEBI:27338', 'CL:0000125', 'PR:000007939', 'PR:000007939', 'PR:000007939', 'PR:000007939']
16279840	84	['After rehydration through graded alcohols into tap water, endogenous peroxidase activity was quenched by incubation with 3% hydrogen peroxide in methanol.']	(16181, 16335)	['CHEBI:30879', 'CHEBI:15377', 'CHEBI:16240', 'CHEBI:16240', 'CHEBI:17790']
16279840	85	['Slides were microwaved for 5–7 min in water, cooled for 5 min, then washed in TBS.']	(16336, 16418)	['CHEBI:15377']
16279840	86	['Nonspecific staining was blocked for 1 h with 3% normal goat serum and 0.1% Triton-X 100 in TBS.']	(16419, 16515)	['CHEBI:9750', 'CHEBI:9750', 'CHEBI:9750', 'CHEBI:9750', 'NCBITaxon:9925', 'UBERON:0001977']
16279840	87	['Slides were then placed into primary antibody (rabbit anti-Aβ peptide polyclonal antibody, Zymed Laboratories, South San Francisco, California, United States; rabbit anti-ubiquitin and rabbit anti–glial fibrillary acidic protein (GFAP) polyclonal antibodies, Dako, Carpinteria, California, United States) diluted 1:500 in TBS with 2% normal goat serum and incubated overnight at room temperature.']	(16516, 16912)	['CHEBI:37527', 'CL:0000125', 'GO:0042571', 'GO:0042571', 'GO:0042571', 'NCBITaxon:9986', 'NCBITaxon:9986', 'NCBITaxon:9986', 'NCBITaxon:9925', 'PR:000007939', 'PR:000007939', 'PR:000007939', 'PR:000007939', 'PR:000007939', 'UBERON:0001977']
16279840	88	["After being washed of excess primary antibody with several changes of TBS, slides were incubated with either the Vectastain Elite anti-rabbit secondary system (anti-Aβ; Vector Laboratories, Burlingame, California, United States) or peroxidase/anti-peroxidase reagents (anti-ubitquitin and anti-GFAP; Sternberger Monoclonals, Lutherville, Maryland, United States) according to the manufacturers' directions."]	(16913, 17319)	['CHEBI:33893', 'GO:0042571', 'NCBITaxon:9986', 'PR:000007939']
16279840	89	['Antibody binding was visualized with diaminobenzidene, and sections were counterstained with hematoxylin.']	(17320, 17425)	['CHEBI:51686', 'GO:0042571']
16279840	90	['Filter Trap Assay\n\nAn aliquot of each cortical homogenate used for Western blotting above was partially solubilized by the addition of SDS to a final concentration of 1%.']	(17427, 17597)	['CHEBI:8984', 'UBERON:0001851']
16279840	91	['Serial 1:2 dilutions were made with 1× PBS/1% SDS, and 100 μl of each dilution was then vacuum-filtered through a pre-wet 0.22-μm cellulose acetate membrane (Schleicher and Schuell) [22].']	(17598, 17785)	['CHEBI:8984']
16279840	92	['Each well was washed several times with PBS, after which blots were incubated overnight with polyclonal anti-Aβ antibody (Zymed Laboratories) diluted 1:600 in a blocking solution of 1× TBS/5% nonfat dry milk powder.']	(17786, 18001)	['CHEBI:75958', 'GO:0042571', 'UBERON:0001913']
16279840	93	['After washing the blots three times for 10 min each in 1× TBS/0.1% Tween-20, the membrane was incubated for 1 h with HRP-conjugated protein A (Sigma) diluted 1:5,000 in blocking solution.']	(18002, 18189)	['CHEBI:53424', 'CHEBI:53424', 'CHEBI:53424', 'CHEBI:75958', 'MOP:0000779', 'PR:000029158', 'PR:000029158']
16279840	94	['The membranes were again washed three times with 1× TBS/0.1% Tween-20, before antibody binding was detected with enhanced chemiluminescence (PerkinElmer, Boston, Massachusetts, United States).']	(18190, 18382)	['CHEBI:53424', 'CHEBI:53424', 'CHEBI:53424', 'GO:0042571']
16279840	95	['Digital images of each blot were captured with a Molecular Imager FX gel documentation system, and the intensity of Aβ staining was quantified using Quantity One image analysis software.']	(18383, 18569)	[]
16279840	96	['Aβ ELISA\n\nAn aliquot of cortical homogenate generated for Western analysis described above was subjected to a three-step sequential extraction using PBS, 2% SDS, and 70% formic acid (FA).']	(18571, 18758)	['CHEBI:8984', 'CHEBI:30751', 'CHEBI:30751', 'CHEBI:30751', 'UBERON:0001851']
16279840	97	['At each step, the sample was sonicated in appropriate buffer and centrifuged at 100,000g for 30 min (1- to 1.5-mo samples) or 60 min (6- to 12-mo samples) at 4 °C as previously described [23–25].']	(18759, 18954)	[]
16279840	98	['The supernatant was removed for analysis, and the pellet was sonicated in the next solution in sequence.']	(18955, 19059)	['CHEBI:75958']
16279840	99	['The 2% SDS extracts were diluted in EC buffer, and the FA extracts neutralized with 1M Tris-phosphate buffer (pH 11) then diluted with EC buffer prior to testing.']	(19060, 19222)	['CHEBI:8984', 'CHEBI:30751', 'CHEBI:9754']
16279840	100	['Human Aβ was measured in each fraction using BAN50 for capture (epitope Aβ1–16) and BA27 and BC05 for detection (Aβ40 and Aβ42, respectively) (Takeda Chemical Industries, Osaka, Japan).']	(19223, 19408)	['NCBITaxon:9606']
16279840	101	['Total Aβ (mouse + human; 1- to 1.5-mo samples only) was measured in each fraction using BNT77 for capture (epitope Aβ11–28) and BA27 and BC05 for detection.']	(19409, 19565)	['NCBITaxon:10088', 'NCBITaxon:9606']
16279840	102	['All values were calculated as picomoles per gram based on the initial weight of cortical tissue.']	(19566, 19662)	['UBERON:0001851', 'UBERON:0000479']
16279840	103	['Activity Monitoring\n\nDaily basal activity was studied in 28 CaMKIIα-tTA × tet-APPswe/ind line 107 mice between 4 and 5 mo of age.']	(19664, 19793)	['NCBITaxon:10088', 'PR:000003199']
16279840	104	['Animals were separated into individual cages immediately before the start of each experiment (n = 3–6 per genotype untreated, 2–5 per genotype dox-reared).']	(19794, 19949)	['CHEBI:50845', 'NCBITaxon:33208']
16279840	105	['The cages were placed inside activity-monitoring frames designed to count every time the animal passed through one of three photobeams spanning the width of the cage (San Diego Instruments, San Diego, California, United States).']	(19950, 20178)	['NCBITaxon:33208']
16279840	106	['Experiments were started midway through the light phase of the day, and data were collected in 1-h bins for the following 48 h. Testing rooms were maintained on the same 13:11 h day:night cycle as the main animal housing areas and were closed to entry during the experiment.']	(20179, 20453)	['NCBITaxon:33208']
16279840	107	["Statistical Analyses\n\nStatistical analyses of protein expression, ELISA data, and filter trap assays were performed by ANOVA with Tukey's honest significant difference post-hoc test applied to significant main effects or interactions (Statistica 6.0, StatSoft, Tulsa, Oklahoma, United States)."]	(20455, 20748)	['GO:0010467']
16279840	108	['In cases of positively skewed data distribution, log10(x + 0.5) transformation was applied to the raw data before submitting them to ANOVA.']	(20749, 20888)	[]
16279840	109	['Results\n\nWe used the tet-off transgene system to express a double mutant version of chimeric mo/huAPP695 (swe/ind KM570, 571NL, and V617F) from a tetracycline-responsive promoter [12,13].']	(20890, 21077)	['CHEBI:27902', 'GO:0010467', 'NCBITaxon:10088', 'SO:0000902', 'SO:0000167']
16279840	110	['Transgenic APP expression was activated by crossing the APPswe/ind mice to animals producing tTA under control of the CaMKIIα promoter [16].']	(21078, 21218)	['GO:0010467', 'GO:0065007', 'NCBITaxon:10088', 'NCBITaxon:33208', 'PR:000004168', 'PR:000003199', 'SO:0000167']
16279840	111	['After initial screening of founders, we identified four lines of tet-APPswe/ind mice that produced very high levels of transgene product in offspring coexpressing tTA (Figures 1 and Figure S1).']	(21219, 21412)	['GO:0010467', 'NCBITaxon:10088', 'SO:0000902']
16279840	112	['Compared to a standard APP transgenic line used for previous amyloid studies by our laboratory (line C3–3; [15,26,27]), we estimated that the four controllable lines produce transgenic APP protein at 10- to 30-fold over endogenous levels (Figure S1).']	(21413, 21663)	['CHEBI:60425', 'PR:000004168', 'PR:000004168']
16279840	113	['This estimate was confirmed by direct comparison of APP levels in nontransgenic and tet-off APP mice using an antibody that recognizes both endogenous APP (and amyloid precursor-like protein 2) and the transgenic protein (monoclonal antibody 22C11; Figure 1D).']	(21664, 21924)	['GO:0042571', 'GO:0042571', 'NCBITaxon:10088', 'PR:000004168', 'PR:000004168', 'PR:000004168', 'PR:000004137', 'PR:000004137', 'PR:000004137', 'PR:000004137', 'PR:000004137', 'PR:000004137']
16279840	114	['Importantly, all four new lines of tet-off APP mice showed nearly complete suppression of the transgene following dox treatment (Figures 1 and Figure S1).']	(21926, 22080)	['CHEBI:50845', 'NCBITaxon:10088', 'PR:000004168', 'SO:0000902']
16279840	115	['We focused on one of the four lines, line 107, to examine in more detail the time dependence and extent of transgene suppression following either acute or chronic treatment with dox.']	(22081, 22263)	['CHEBI:50845', 'SO:0000902']
16279840	116	['Two dox-treated groups were compared to two untreated groups: one group of mice was born and raised on dox, a second group was treated with dox for 2 wk starting at 1 mo of age (4 wk + 2 wk dox); two untreated groups kept on normal chow were harvested at either 4 or 6 wk of age.']	(22264, 22543)	['CHEBI:50845', 'CHEBI:50845', 'CHEBI:50845', 'CHEBI:50845', 'CHEBI:33290', 'GO:0007567', 'NCBITaxon:10088']
16279840	117	['Animals born and raised on dox harbored no transgenic APP (Figure 1A).']	(22544, 22614)	['CHEBI:50845', 'GO:0007567', 'NCBITaxon:33208', 'PR:000004168']
16279840	118	['Following as little as 2 wk of dox treatment, transgenic APP expression was reduced by more than 95% compared to pre-dox levels.']	(22615, 22743)	['CHEBI:50845', 'CHEBI:50845', 'GO:0010467', 'PR:000004168']
16279840	119	['The residual expression remaining in acutely treated mice represents less than 4% of the transgenic protein produced in the absence of dox (Figure 1C), and likely results from slight leakage at the level of transcription (data not shown).']	(22744, 22982)	['CHEBI:50845', 'GO:0010467', 'NCBITaxon:10088']
16279840	120	['Importantly, the total amount of APP (endogenous plus transgenic) and related APLPs in both acute and chronically treated animals was statistically indistinguishable from that in nontransgenic mice (Figure 1D; statistical analyses for experiments throughout the study are presented in the accompanying figure legends).']	(22983, 23301)	['NCBITaxon:33208', 'NCBITaxon:10088', 'PR:000004168']
16279840	121	['To ensure that Aβ production was suppressed in concert with the dox-mediated inhibition of its precursor APPswe/ind, we measured Aβ40 and Aβ42 levels by ELISA in forebrain homogenates from young tet-off animals.']	(23303, 23514)	['CHEBI:50845', 'GO:0034205', 'GO:0034205', 'NCBITaxon:33208', 'UBERON:0001890']
16279840	122	['At 1 mo of age, the mice lacked visible amyloid aggregates that might act as an intractable reservoir of peptide remaining in the brain after the transgene had been suppressed.']	(23515, 23691)	['CHEBI:60425', 'NCBITaxon:10088', 'SO:0000902', 'UBERON:0000955']
16279840	123	['To further ensure we could detect any such insoluble aggregates that might bias our measure of changes in peptide synthesis, we performed a sequential three-step extraction with PBS, 2% SDS, and 70% FA that would separate peptides by solubility.']	(23692, 23937)	['CHEBI:8984', 'CHEBI:30751', 'GO:0043043', 'GO:0043043']
16279840	124	['We compared the levels of human transgene-derived Aβ40 and Aβ42 in untreated mice at 4 and 6 wk of age to animals that had either been born and raised on dox or that had been left untreated for 4 wk and then placed on dox chow for 2 wk prior to harvest (the same groups described above for immunoblot analysis of APPswe/ind levels, line 107).']	(23938, 24280)	['CHEBI:50845', 'CHEBI:50845', 'CHEBI:33290', 'GO:0007567', 'NCBITaxon:9606', 'NCBITaxon:10088', 'NCBITaxon:33208', 'SO:0000902']
16279840	125	['Consistent with the reduction in full-length APPswe/ind synthesis shown by immunoblot (see Figure 1), we found that transgene-derived Aβ levels were completely suppressed in animals born and raised on dox, and were sharply reduced following acute (2 wk) antibiotic treatment.']	(24281, 24556)	['CHEBI:50845', 'CHEBI:33282', 'GO:0007567', 'NCBITaxon:33208', 'SO:0000902']
16279840	126	['Compared to the levels in untreated 4-wk-old mice, PBS-soluble Aβ42 dropped by 95.2% following 2 wk of dox treatment and by 99.2% with chronic treatment (Figure 2A).']	(24557, 24722)	['CHEBI:50845', 'NCBITaxon:10088']
16279840	127	['Similarly, SDS-soluble Aβ42 decreased by 75.2% and 94.8% following 2-wk or lifelong dox treatment (Figure 2B).']	(24723, 24833)	['CHEBI:8984', 'CHEBI:50845']
16279840	128	['Only the FA fraction revealed a small dox-resistant pool of peptide in acutely treated animals that we believe represents stable predeposit aggregates that have already accumulated by 4 wk of age when treatment was begun (Figure 2C).']	(24834, 25067)	['CHEBI:30751', 'CHEBI:50845', 'NCBITaxon:33208']
16279840	129	['Indeed, animals that were born and raised on dox did not harbor this reservoir of treatment-resistant peptide, with 96.3% less Aβ42 than untreated 4-wk-old mice.']	(25068, 25229)	['CHEBI:50845', 'GO:0007567', 'NCBITaxon:33208', 'NCBITaxon:10088']
16279840	130	['Measurement of total Aβ in chronically treated mice, including endogenous and transgene-derived peptide, demonstrated that Aβ levels in tet-off APP mice were reduced to the level of endogenous peptide found in nontransgenic animals (Figure 2D).']	(25230, 25474)	['NCBITaxon:10088', 'NCBITaxon:10088', 'NCBITaxon:33208', 'PR:000004168', 'SO:0000902']
16279840	131	['Taken together with the immunoblotting data for full-length APPswe/ind, the ELISA measurements indicate that dox-mediated suppression of transgenic APPswe/ind synthesis leads to parallel reduction of Aβ levels.']	(25475, 25685)	['CHEBI:50845']
16279840	132	['The ELISA data also confirmed that incorporation of the Swedish and Indiana mutations led to high levels of Aβ42, which we predicted would induce rapid plaque formation in untreated animals.']	(25687, 25877)	['NCBITaxon:33208']
16279840	133	['Histological characterization of double transgenic (CaMKIIα-tTA × tet-APPswe/ind) mice revealed early-onset amyloid formation in all four new lines.']	(25878, 26026)	['CHEBI:60425', 'NCBITaxon:10088', 'PR:000003199']
16279840	134	['Amyloid plaques were seen in mice as young as 8 wk of age (data not shown).']	(26027, 26102)	['CHEBI:60425', 'NCBITaxon:10088']
16279840	135	['Plaques were limited to the forebrain, including the cortex, hippocampus, olfactory bulb, and striatum, where the CaMKIIα promoter is known to be most active [16,28] (Figure S2).']	(26103, 26281)	['GO:0007608', 'PR:000003199', 'SO:0000167', 'UBERON:0001890', 'UBERON:0001851', 'UBERON:0002264', 'UBERON:0002264', 'UBERON:0002435']
16279840	136	['By 6 mo of age, amyloid burden became severe, covering large areas of the cortex and hippocampus (Figure S3).']	(26282, 26391)	['CHEBI:60425', 'UBERON:0001851']
16279840	137	['No lesions were seen in the cerebellum or brain stem even at late ages, consistent with CaMKIIα-controlled transgene expression.']	(26392, 26520)	['GO:0065007', 'GO:0010467', 'PR:000003199', 'SO:0000902', 'UBERON:0002037', 'UBERON:0002298', 'UBERON:0002298']
16279840	138	['Unlike what is thought to occur in the human disease, the first visible plaques in the tet-off APP mice are fibrillar-cored deposits.']	(26521, 26654)	['NCBITaxon:9606', 'NCBITaxon:10088', 'PR:000004168']
16279840	139	['We have noted the same early appearance of cored deposits in other lines of APP transgenic mice that harbor the Swedish mutation [27].']	(26655, 26789)	['NCBITaxon:10088', 'PR:000004168']
16279840	140	['Diffuse plaques were apparent in 6-mo-old tTA/APP mice, and became relatively abundant by 9 mo of age.']	(26790, 26892)	['NCBITaxon:10088', 'PR:000004168']
16279840	141	['At older ages (9–12 mo) amyloid deposits were visible in the thalamus, which has also been observed in mice expressing mutant APP via the Thy-1 promoter.']	(26893, 27046)	['CHEBI:60425', 'GO:0010467', 'NCBITaxon:10088', 'PR:000004168', 'PR:000001843', 'PR:000001843', 'PR:000001843', 'SO:0000167', 'UBERON:0001897']
16279840	142	['The presence of amyloid pathology in this region has been attributed to axonal transport of APP/Aβ to the terminals of cortical neurons in the thalamus [29].']	(27047, 27204)	['CHEBI:60425', 'CL:0010012', 'CL:0010012', 'GO:0008088', 'GO:0008088', 'GO:0030424', 'PR:000004168', 'UBERON:0001851', 'UBERON:0001897']
16279840	143	['Most importantly, only double transgenic mice, expressing both the tTA and APP transgenes, developed amyloid lesions.']	(27205, 27322)	['CHEBI:60425', 'GO:0010467', 'NCBITaxon:10088', 'PR:000004168', 'SO:0000902']
16279840	144	['Single transgenic mice up to 15 mo of age showed no sign of pathology (Figure S3).']	(27323, 27405)	['NCBITaxon:10088']
16279840	145	['Similarly, amyloid pathology can be completely prevented in double transgenic animals born and raised on dox.']	(27406, 27515)	['CHEBI:60425', 'CHEBI:50845', 'GO:0007567', 'NCBITaxon:33208']
16279840	146	['Animals from our highest expressing line (line 885) maintained on dox for up to 1 y harbored no amyloid pathology (data not shown), indicating that residual leakage of transgene expression in the presence of dox does not provide sufficient Aβ peptide to induce amyloid formation even over long periods.']	(27516, 27818)	['CHEBI:50845', 'CHEBI:60425', 'CHEBI:50845', 'CHEBI:60425', 'GO:0010467', 'GO:0010467', 'NCBITaxon:33208', 'SO:0000902']
16279840	147	['To mimic therapeutic intervention with inhibitors of Aβ production, we raised a group of 25 double transgenic mice (CaMKIIα-tTA × APP line 107) on normal food until 6 mo of age, when we knew amyloid formation was already well underway in the brain.']	(27820, 28068)	['CHEBI:35222', 'CHEBI:33290', 'CHEBI:60425', 'GO:0034205', 'GO:0034205', 'NCBITaxon:10088', 'PR:000003199', 'PR:000004168', 'UBERON:0000955']
16279840	148	['At 6 mo, half of the animals were switched from normal chow to food containing dox at 200 mg/kg until they were sacrificed at 9 or 12 mo of age.']	(28069, 28213)	['CHEBI:33290', 'CHEBI:33290', 'CHEBI:50845', 'NCBITaxon:33208']
16279840	149	['The remaining control animals were kept on standard chow (untreated).']	(28214, 28283)	['CHEBI:33290', 'NCBITaxon:33208']
16279840	150	['In all, four cohorts were created: 6 mo untreated (n = 7), 9 mo untreated (n = 5), 6 mo + 3 mo treated (n = 8), and 6 mo + 6 mo treated (n = 5).']	(28284, 28428)	[]
16279840	151	['Full suppression (>95%) of transgenic APPswe/ind levels in the dox-treated animals was confirmed by immunoblot (Figure 3).']	(28429, 28551)	['CHEBI:50845', 'NCBITaxon:33208']
16279840	152	['To ensure that the transgene could be suppressed as rapidly in 6-mo-old mice with fulminant pathology as it can in young, predeposit animals, we treated an additional set of 6-mo-old animals with dox for 1 wk prior to harvest.']	(28552, 28778)	['CHEBI:50845', 'NCBITaxon:10088', 'NCBITaxon:33208', 'NCBITaxon:33208', 'SO:0000902']
16279840	153	['Importantly, both APPswe/ind and APP–C-terminal fragment levels were fully suppressed after only 1 wk of treatment, indicating that the in vivo half-life of APPswe/ind and its processed C-terminal fragments are relatively short (Figure 3D).']	(28779, 29019)	['PR:000004168']
16279840	154	['Tissue sections from each animal in the four treatment groups were stained for amyloid pathology by Hirano silver, Campbell-Switzer silver, thioflavin-S, and Aβ immunohistochemistry.']	(29021, 29203)	['CHEBI:60425', 'NCBITaxon:33208', 'UBERON:0000479']
16279840	155	['As expected, the 6 mo untreated cohort displayed moderate amyloid pathology, and the 9 mo untreated cohort progressed to a severe amyloid burden.']	(29204, 29349)	['CHEBI:60425', 'CHEBI:60425']
16279840	156	['In contrast, the extent of amyloid pathology in mice from the 6 mo + 3 mo treated or 6 mo + 6 mo treated cohorts closely resembled that of the 6 mo untreated cohort, despite the significant age difference between the treated and untreated groups (Figures 4 and Figure S3).']	(29350, 29622)	['CHEBI:60425', 'NCBITaxon:10088']
16279840	157	['Well-formed plaques remained in the treated animals after 6 mo of transgene suppression, even though as much time was given to clear the lesions as they had taken to form.']	(29623, 29794)	['NCBITaxon:33208', 'SO:0000902']
16279840	158	['Moreover, both types of amyloid, diffuse and fibrillar, remained intact throughout treatment.']	(29795, 29888)	['CHEBI:60425']
16279840	159	['Using the Campbell-Switzer silver stain to distinguish different forms of amyloid, we found diffuse plaques were as persistent as cored deposits (Figure S4).']	(29889, 30046)	['CHEBI:60425']
16279840	160	['It was nevertheless clear that dox-induced suppression of transgenic APP had completely halted the progression of pathology.']	(30047, 30171)	['CHEBI:50845', 'PR:000004168']
16279840	161	['To confirm that the arrest of plaques without any sign of clearance was not unique to the line 107 mice, we repeated the dox-suppression experiment in a second line of tet-off APP mice (CaMKIIα-tTA × tet-APPswe/ind line 18; n = 22).']	(30173, 30405)	['CHEBI:50845', 'NCBITaxon:10088', 'NCBITaxon:10088', 'PR:000004168', 'PR:000003199']
16279840	162	['Again, long-term dox treatment was begun at 6 mo of age, and mice were harvested after 3 mo of transgene suppression (6 mo untreated, n = 8; 9 mo untreated, n = 6; 6 mo + 3 mo treated, n = 8).']	(30406, 30598)	['CHEBI:50845', 'NCBITaxon:10088', 'SO:0000902']
16279840	163	['Immunoblotting for APP confirmed full transgene suppression in the treated animals (Figure S5).']	(30599, 30694)	['NCBITaxon:33208', 'PR:000004168', 'SO:0000902']
16279840	164	['As in the line 107 mice described above, amyloid burden worsened substantially in the untreated mice between 6 and 9 mo of age.']	(30695, 30822)	['CHEBI:60425', 'NCBITaxon:10088', 'NCBITaxon:10088']
16279840	165	['Suppression of transgene expression abruptly arrested progression of pathology (Figure S6), but again without any sign of reduction.']	(30823, 30955)	['GO:0010467', 'SO:0000902']
16279840	166	['Both silver- and thioflavin-S-positive plaques could still be found in each of the dox-treated animals.']	(30956, 31059)	['CHEBI:50845', 'NCBITaxon:33208']
16279840	167	['We biochemically measured the amount of aggregated Aβ in the brains of our mice before and after transgene suppression using filter trap analysis of cortical tissue from each animal.']	(31061, 31243)	['NCBITaxon:10088', 'NCBITaxon:33208', 'SO:0000902', 'UBERON:0000955', 'UBERON:0001851', 'UBERON:0000479']
16279840	168	['In this assay, serial dilutions of protein homogenate are passed through a cellulose acetate filter; particles larger than the pore size of the filter become trapped in the membrane and are revealed by immunoblotting [22].']	(31244, 31466)	[]
16279840	169	['Consistent with our visual analysis of the histological sections, line 107 tTA/APP mice treated with dox for 3 or 6 mo had the same amount of aggregated Aβ as when they started treatment at 6 mo of age (Figure 4A and 4B).']	(31467, 31688)	['CHEBI:50845', 'GO:0007601', 'NCBITaxon:10088', 'PR:000004168']
16279840	170	['In contrast, untreated 9-mo-old mice had almost twice as much aggregated Aβ as either of the treated groups.']	(31689, 31797)	['NCBITaxon:10088']
16279840	171	['Filter trap analysis of line 18 tTA/APP mice yielded similar results: the increase in aggregated Aβ observed in untreated animals between 6 and 9 mo of age was completely arrested by transgene suppression (Figure S5C and S5D).']	(31798, 32024)	['NCBITaxon:10088', 'NCBITaxon:33208', 'PR:000004168', 'SO:0000902']
16279840	172	['We next used ELISA to measure total Aβ in the brains of each group to determine whether any change in the amount or solubility of peptide occurred while APPswe/ind expression was suppressed.']	(32026, 32216)	['GO:0010467', 'UBERON:0000955']
16279840	173	['Cortical homogenates were sequentially extracted to separate peptide into PBS-, SDS-, and FA-soluble fractions, then transgene-derived Aβ40 and Aβ42 were measured by human-specific ELISA [23].']	(32217, 32409)	['CHEBI:8984', 'CHEBI:30751', 'NCBITaxon:9606', 'SO:0000902', 'UBERON:0001851']
16279840	174	['In all animals harboring amyloid deposits, we found that the vast majority of Aβ (>99%) was extracted into the SDS and FA fractions (Figure 5A and 5B).']	(32410, 32561)	['CHEBI:60425', 'CHEBI:8984', 'CHEBI:30751', 'NCBITaxon:33208']
16279840	175	['Consistent with the filter trap results presented above, there were no significant differences in SDS- or FA-soluble Aβ between the 6 mo untreated cohort and either the 6 mo + 3 mo treated or 6 mo + 6 mo treated cohorts.']	(32562, 32782)	['CHEBI:8984', 'CHEBI:30751']
16279840	176	['However, brains of both 6 mo + 3 mo and 6 mo + 6 mo treated cohorts contained roughly twice as much PBS-soluble Aβ40 as untreated 6-mo-old mice (Figure 5C).']	(32783, 32939)	['NCBITaxon:10088', 'UBERON:0000955']
16279840	177	['Levels of Aβ42 showed a similar trend, but did not reach statistical significance.']	(32940, 33022)	[]
16279840	178	['In fact, levels of PBS-soluble Aβ40 and Aβ42 in the 6 mo + 3 mo and 6 mo + 6 mo treated cohorts were most similar to that of the 9 mo untreated cohort, suggesting that age, as opposed to synthetic rate (which would be negligible in the treated animals), may determine the fraction of PBS-soluble Aβ in these animals.']	(33023, 33339)	['NCBITaxon:33208', 'NCBITaxon:33208']
16279840	179	['We also assessed neuritic and glial pathology surrounding the plaques to determine whether there were any changes in nearby tissue following long-term transgene suppression.']	(33341, 33514)	['CL:0000125', 'GO:0043005', 'SO:0000902']
16279840	180	['Both Hirano silver stain and ubiquitin immunostaining showed neuritic pathology in all treatment groups (Figure 6).']	(33515, 33630)	['GO:0043005']
16279840	181	['Similarly, activated astrocytes immunostained for GFAP were found near plaques in all animals (Figure 6).']	(33631, 33736)	['CL:0002627', 'CL:0002627', 'NCBITaxon:33208', 'PR:000007939']
16279840	182	['Neuritic and glial pathology were more severe in the older untreated mice.']	(33737, 33811)	['CL:0000125', 'GO:0043005', 'NCBITaxon:10088']
16279840	183	['In contrast, transgene suppression prevented the growth of individual deposits apparent in untreated mice, and limited the surrounding pathology to what was already present when treatment began.']	(33812, 34006)	['NCBITaxon:10088', 'SO:0000902']
16279840	184	['An obvious question we sought to address was whether the deposition of Aβ diminished cognitive ability in untreated mice, and what might happen to cognition when the process was interrupted.']	(34008, 34198)	['GO:0050890', 'GO:0050890', 'NCBITaxon:10088']
16279840	185	['Unfortunately, efforts to characterize cognitive behavior were compromised by severe hyperactivity in untreated double transgenic mice.']	(34199, 34334)	['GO:0050890', 'NCBITaxon:10088']
16279840	186	['The tTA/APP animals were often seen running in circles around the perimeter of their cages, and a similar swimming pattern was noted when the mice were tested in the Morris water maze.']	(34335, 34519)	['CHEBI:15377', 'GO:0036268', 'NCBITaxon:33208', 'NCBITaxon:10088', 'PR:000004168']
16279840	187	['In the radial water maze, repetitive swim patterns were noted with no evidence of choice-motivated actions.']	(34520, 34627)	['CHEBI:15377', 'GO:0036268']
16279840	188	['Other studies have dealt with similar problems by excluding animals that do not show adequate attention to the task, retaining only those mice that meet certain performance criteria [30].']	(34628, 34815)	['NCBITaxon:33208', 'NCBITaxon:10088']
16279840	189	['In our case, the penetrance of hyperactivity was close to 100%, leaving us with no testable animals.']	(34816, 34916)	['NCBITaxon:33208']
16279840	190	['This phenotype has not affected previous lines of APPswe mice we have produced, such as lines E1–2 or C3–3, that express lower levels of transgenic protein.']	(34917, 35073)	['GO:0010467', 'NCBITaxon:10088']
16279840	191	['Indeed, in past studies where hyperactivity was not a factor, we established a clear relationship between amyloid load and cognitive ability [31].']	(35074, 35220)	['CHEBI:60425', 'GO:0050890']
16279840	192	["However, in the current study, we feel that although the poor performance of the tTA/APP mice in the maze tests could technically be scored as cognitive impairment, the animals' severe hyperactivity made interpretation of the cognitive tasks impossible."]	(35221, 35474)	['GO:0050890', 'GO:0050890', 'NCBITaxon:10088', 'NCBITaxon:33208', 'PR:000004168']
16279840	193	['In order to understand the nature and extent of hyperactivity in the tTA/APP mice, we quantified daily activity levels in double transgenic animals along with their single transgenic and nontransgenic siblings using four-beam frames designed to monitor ambulation within an enclosed cage.']	(35476, 35764)	['GO:0040011', 'NCBITaxon:10088', 'NCBITaxon:33208', 'PR:000004168']
16279840	194	['As shown in Figure 7, the double transgenic mice were up to 10-fold more active during the dark phase of the day–night cycle than any of the control groups.']	(35765, 35921)	['NCBITaxon:10088']
16279840	195	['Activity levels appeared to follow a relatively normal diurnal cycle, decreasing substantially during the daylight hours.']	(35922, 36043)	['GO:0007623', 'GO:0007623']
16279840	196	['However, even during the light phase, the tTA/APP mice remained many-fold more active than normal controls.']	(36044, 36151)	['NCBITaxon:10088', 'PR:000004168']
16279840	197	['This behavior was partially, but not consistently, reversed by 1 mo of transgene suppression beginning at 4–5 mo of age (data not shown).']	(36152, 36289)	['SO:0000902']
16279840	198	['In contrast, hyperactivity was completely abolished by rearing tTA/APP mice on dox.']	(36290, 36373)	['CHEBI:50845', 'NCBITaxon:10088', 'PR:000004168']
16279840	199	['Animals born and raised on dox showed activity levels similar to the untreated controls (Figure 7C).']	(36374, 36474)	['CHEBI:50845', 'GO:0007567', 'NCBITaxon:33208']
16279840	200	['Intriguingly, all of the dox-reared animals, both transgenic and wild-type, showed altered circadian rhythms with far less distinction between their day- and nighttime activity levels.']	(36475, 36659)	['CHEBI:50845', 'GO:0007623', 'GO:0007623', 'NCBITaxon:33208']
16279840	201	['Discussion\n\nWe present a new mouse model for AD that was designed to test the consequences of inhibiting Aβ production after the onset of amyloid pathology.']	(36661, 36817)	['CHEBI:60425', 'GO:0034205', 'GO:0034205', 'NCBITaxon:10088']
16279840	202	['New lines of transgenic mice were developed for this study that express high levels of APPswe/ind under the control of a tetracycline-responsive promoter.']	(36818, 36972)	['CHEBI:27902', 'GO:0010467', 'GO:0065007', 'NCBITaxon:10088', 'SO:0000167']
16279840	203	['We demonstrate that treatment with dox suppresses steady-state levels of both APPswe/ind and its C-terminal fragments, indicating that the mutant proteins have a relatively short half-life in vivo.']	(36973, 37170)	['CHEBI:50845']
16279840	204	['Transgenic expression of APPswe/ind and consequent overproduction of Aβ42 cause early-onset amyloid deposition in untreated mice, in which deposits appear as early as 2 mo of age.']	(37171, 37350)	['CHEBI:60425', 'GO:0010467', 'NCBITaxon:10088']
16279840	205	['Amyloid burden worsens significantly with age, and by 9 mo, the hippocampus and cortex of untreated mice are largely filled with aggregated peptide.']	(37351, 37499)	['CHEBI:60425', 'NCBITaxon:10088', 'UBERON:0001851']
16279840	206	['We find that suppression of transgenic APP by more than 95% abruptly halts the progression of amyloid pathology.']	(37500, 37612)	['CHEBI:60425', 'PR:000004168']
16279840	207	['Importantly, this outcome occurs in animals already harboring considerable amyloid pathology, a situation similar to what might be expected in patients to be treated with secretase inhibitors.']	(37613, 37805)	['CHEBI:60425', 'CHEBI:35222', 'NCBITaxon:33208']
16279840	208	['Somewhat unexpectedly, we observe no appreciable clearance of deposited amyloid even following periods of transgene suppression equal to the time taken for plaques to form.']	(37806, 37978)	['CHEBI:60425', 'SO:0000902']
16279840	209	['This latter finding indicates that compared to other disease-associated protein aggregates such as mutant huntingtin, which clear in less than 3 mo [32], the disaggregation of extracellular amyloid is relatively slow.']	(37979, 38196)	['CHEBI:60425', 'GO:0005576', 'PR:000008840']
16279840	210	['Notably, pharmaceutical γ-secretase inhibitors published to date show less strict regulation of Aβ production following chronic administration than we have attained here.']	(38198, 38368)	['CHEBI:52217', 'CHEBI:35222', 'GO:1902003', 'GO:1902003', 'GO:1902003', 'GO:1902003', 'GO:0070765', 'GO:0070765', 'GO:0070765']
16279840	211	['Two independent compounds tested in Tg2576 [33] and TgCRND8 [34] transgenic mice show no more than 85% suppression of Aβ40 levels, and where measured, even less suppression of Aβ42 (approximately 60%) [35,36].']	(38369, 38578)	['CHEBI:36357', 'NCBITaxon:10088']
16279840	212	['Thus, even after accounting for the much higher APP expression levels in our mice than in the Tg2576 and TgCRND8 lines, we have achieved better absolute suppression of Aβ production with the tet-off system than is currently possible with published γ-secretase inhibitors.']	(38579, 38850)	['CHEBI:35222', 'GO:0010467', 'GO:0034205', 'GO:0034205', 'GO:0070765', 'GO:0070765', 'GO:0070765', 'NCBITaxon:10088', 'PR:000004168']
16279840	213	['Since even the most advanced future pharmaceutical agents are unlikely to attain more complete control of Aβ production than achieved here, this system provides a salient test of therapeutic intervention with Aβ-lowering compounds.']	(38851, 39082)	['CHEBI:52217', 'CHEBI:52217', 'CHEBI:36357', 'GO:1902003', 'GO:1902003', 'GO:1902003', 'GO:1902003']
16279840	214	['Although the progression of amyloid deposition was sharply arrested by this approach, we found that a substantial amyloid burden remained even after long periods of transgene suppression.']	(39084, 39271)	['CHEBI:60425', 'CHEBI:60425', 'SO:0000902']
16279840	215	['We examined a small number of animals after 12 mo of dox treatment (beginning at 6 mo of age), and found that amyloid deposits were still relatively abundant.']	(39272, 39430)	['CHEBI:50845', 'CHEBI:60425', 'NCBITaxon:33208']
16279840	216	['Longer-term treatments are now in progress.']	(39431, 39474)	[]
16279840	217	['At the latest treatment interval analyzed by ELISA, animals administered dox for 6 mo showed elevated levels of PBS-soluble Aβ (see Figure 5) that could be interpreted as an indication that the plaques are slowly releasing peptide (or oligomeric Aβ) into the soluble pool and might eventually dissolve.']	(39475, 39777)	['CHEBI:50845', 'NCBITaxon:33208']
16279840	218	['Whether inhibiting Aβ production longer than 6 (or 12) mo may ultimately result in clearance of amyloid is under investigation; unfortunately, the life span of the model eventually limits this experiment.']	(39778, 39982)	['CHEBI:60425', 'GO:0034205', 'GO:0034205', 'UBERON:0000104', 'UBERON:0000104']
16279840	219	['Therapeutics used in humans will have considerably more time to act than is possible within the life span of rodent models.']	(39983, 40106)	['NCBITaxon:9606', 'NCBITaxon:9989', 'UBERON:0000104', 'UBERON:0000104']
16279840	220	['Long-term treatments would certainly be possible and could be a key to effective therapy.']	(40107, 40196)	[]
16279840	221	['Overall, however, we interpret our findings as evidence that AD therapies that significantly lower the production of Aβ (by either inhibiting secretase activity or inhibiting APP expression) may not quickly reverse preexisting pathology, but should effectively halt further deposition of amyloid.']	(40197, 40493)	['CHEBI:60425', 'GO:0034205', 'GO:0034205', 'GO:0034205', 'GO:0010467', 'PR:000004168']
16279840	222	['In interpreting our study, it should be remembered that the earliest plaques to appear in these mice, like other APP transgenics harboring the Swedish mutation [27], are predominantly fibrillar deposits, which may be less tractable than the diffuse aggregates thought to come first in the course of the human disease.']	(40495, 40812)	['NCBITaxon:10088', 'NCBITaxon:9606', 'PR:000004168']
16279840	223	['However, our data suggest that once diffuse deposits are formed in these mice, they are no more easily cleared in our system than cored plaques (see Figure S4).']	(40813, 40973)	['NCBITaxon:10088']
16279840	224	['An additional consideration we recognize is that a small amount of transgene expression continues in the presence of dox and that endogenous mouse Aβ continues to be produced.']	(40974, 41149)	['CHEBI:50845', 'GO:0010467', 'NCBITaxon:10088', 'SO:0000902']
16279840	225	['It is possible that the combined low levels of endogenous mouse Aβ and nonsuppressed human peptide are sufficient to maintain existing deposits.']	(41150, 41294)	['NCBITaxon:10088', 'NCBITaxon:9606']
16279840	226	['However, these low levels of peptide are not sufficient to induce new amyloid formation, as CaMKIIα-tTA × tetAPPswe/ind mice raised on dox for up to a year do not develop amyloid lesions (data not shown).']	(41295, 41499)	['CHEBI:60425', 'CHEBI:50845', 'CHEBI:60425', 'NCBITaxon:10088', 'PR:000003199']
16279840	227	['It is also clear that in this genetic system, we have raised the production of Aβ to levels not found in humans to accelerate pathology into an experimentally feasible time frame.']	(41500, 41679)	['GO:0034205', 'GO:0034205', 'GO:0034205', 'NCBITaxon:9606', 'SO:0000704']
16279840	228	['This system allowed us to create an approximately 20-fold differential between APP/Aβ synthetic rates before and after treatment, yet the in vivo equilibrium between aggregated and disaggregated states of Aβ still favored the maintenance of amyloid deposits.']	(41680, 41938)	['CHEBI:60425', 'GO:0042983', 'GO:0034205', 'GO:0034205', 'GO:0042983', 'PR:000004168']
16279840	229	['In our opinion, it seems unlikely that amyloid deposits in human brain would be inherently any less stable than those formed in mouse brain.']	(41939, 42079)	['CHEBI:60425', 'NCBITaxon:9606', 'NCBITaxon:10088', 'UBERON:0000955', 'UBERON:0000955']
16279840	230	['However, the human brain may harbor clearance mechanisms not shared by mice that would allow more efficient removal of preexisting amyloid.']	(42080, 42219)	['CHEBI:60425', 'NCBITaxon:9606', 'NCBITaxon:10088', 'UBERON:0000955']
16279840	231	['One potential mechanism by which amyloid may be more efficiently removed in the human disease than in the mouse models is through microglial phagocytosis.']	(42221, 42375)	['CHEBI:60425', 'CL:0000129', 'GO:0006909', 'NCBITaxon:9606', 'NCBITaxon:10088']
16279840	232	['Resident microglia in transgenic mouse models localize to tissue surrounding plaques but show little evidence of amyloid engulfment [37–40].']	(42376, 42516)	['CHEBI:60425', 'CL:0000129', 'NCBITaxon:10088', 'UBERON:0000479']
16279840	233	['In contrast, microglia surrounding amyloid plaques in human brain show a much higher state of activation with greater expression of complement receptor [40].']	(42517, 42674)	['CHEBI:60425', 'CL:0000129', 'GO:0010467', 'NCBITaxon:9606', 'UBERON:0000955']
16279840	234	['Thus, the role of microglia in amyloid metabolism is minor in transgenic models compared to the human condition.']	(42675, 42787)	['CHEBI:60425', 'CL:0000129', 'GO:0008152', 'NCBITaxon:9606']
16279840	235	['Somewhat paradoxically, several studies further demonstrate that treatment with anti-inflammatory drugs to reduce microglial activation actually lowers amyloid load in APP transgenic mice, suggesting a role for mouse microglia in the formation and maintenance of amyloid aggregates [41–43].']	(42788, 43078)	['CHEBI:35472', 'CHEBI:35472', 'CHEBI:35472', 'CHEBI:35472', 'CHEBI:60425', 'CHEBI:60425', 'CL:0000129', 'CL:0000129', 'GO:0001774', 'GO:0001774', 'NCBITaxon:10088', 'NCBITaxon:10088', 'PR:000004168']
16279840	236	['However, this outcome may be alternatively explained by direct effects of many anti-inflammatory drugs on γ-secretase cleavage [44–47].']	(43079, 43214)	['CHEBI:35472', 'CHEBI:35472', 'CHEBI:35472', 'CHEBI:35472', 'GO:0070765', 'GO:0070765', 'GO:0070765', 'MOP:0000780']
16279840	237	['Nonetheless, the role of microglia in both the human condition and the mouse models is poorly understood, and differences in microglial reactivity between the two could lead to significantly faster amyloid clearance in the brains of patients with AD than we observe in the tet-off APP mice.']	(43215, 43505)	['CHEBI:60425', 'CL:0000129', 'CL:0000129', 'NCBITaxon:9606', 'NCBITaxon:10088', 'NCBITaxon:10088', 'PR:000004168', 'UBERON:0000955']
16279840	238	['Given the relatively minor role played by microglia in other mouse models of amyloidosis, we think it unlikely that these cells have influenced the rate of amyloid clearance in the tet-off APP mice.']	(43507, 43705)	['CHEBI:60425', 'CL:0000129', 'NCBITaxon:10088', 'NCBITaxon:10088', 'PR:000004168']
16279840	239	['Even so, we considered the possibility that chronic dox treatment may have altered the activation state of microglia in our treated mice.']	(43706, 43843)	['CHEBI:50845', 'CL:0000129', 'NCBITaxon:10088']
16279840	240	['Dox is structurally similar to minocycline, a reported anti-inflammatory drug and inhibitor of microglial activation [48].']	(43844, 43966)	['CHEBI:50845', 'CHEBI:50694', 'CHEBI:35472', 'CHEBI:35472', 'CHEBI:35472', 'CHEBI:35472', 'CHEBI:35222', 'CL:0000129', 'GO:0001774', 'GO:0001774']
16279840	241	['However, if dox does have anti-inflammatory activity, then, based on previous studies with other anti-inflammatories, we would have expected to find less amyloid in the dox-treated animals.']	(43967, 44156)	['CHEBI:50845', 'CHEBI:67079', 'CHEBI:67079', 'CHEBI:67079', 'CHEBI:60425', 'CHEBI:50845', 'NCBITaxon:33208']
16279840	242	['Clearly, that was not the case.']	(44157, 44188)	[]
16279840	243	['While it is possible that dox acts in some other way to slow amyloid clearance, data from multiple studies demonstrate that microglial responses are normally weak in the mouse AD models [37–40], and thus it is doubtful that dox-mediated microglial inhibition affected the outcome of our study.']	(44189, 44482)	['CHEBI:50845', 'CHEBI:60425', 'CHEBI:50845', 'CL:0000129', 'CL:0000129', 'NCBITaxon:10088']
16279840	244	['The persistence and stability of amyloid deposits in our system is unexpected given the speed with which Aβ aggregates are cleared in other mouse models of therapeutic intervention.']	(44484, 44665)	['CHEBI:60425', 'NCBITaxon:10088']
16279840	245	['Anti-Aβ antibodies injected directly into the brain have been shown to eliminate amyloid deposits in as little as 1 wk after treatment [49–51].']	(44666, 44809)	['CHEBI:60425', 'GO:0042571', 'UBERON:0000955']
16279840	246	['Peripheral antibody injection decreases amyloid load more broadly, and although it does not appear to act as quickly as local injection, can significantly reduce amyloid load within 2 mo of initial treatment [52,53].']	(44810, 45026)	['CHEBI:60425', 'CHEBI:60425', 'GO:0042571']
16279840	247	['More recently, an alternative approach has shown that lentiviral transfer of neprilysin can also reduce the number of aggregates in the area of the injection site [54].']	(45027, 45195)	['NCBITaxon:11646', 'PR:000001898']
16279840	248	['Careful study of the mechanism behind several of the antibody-mediated therapies has suggested that activated microglia play an important role in the removal of fibrillar plaques after immunization [50,52,55].']	(45196, 45405)	['CL:0002629', 'CL:0002629', 'GO:0042571']
16279840	249	['However, it has been noted that deletion of the Fc receptor (the primary receptor for microglial opsinization of antibody–antigen complexes) in APP transgenic mouse models has no impact on the effectiveness of antibody-mediated therapy [56,57].']	(45406, 45650)	['CHEBI:59132', 'CL:0000129', 'GO:0042571', 'GO:0032991', 'GO:0042571', 'NCBITaxon:10088', 'PR:000004168']
16279840	250	['It is, nevertheless, possible that lack of microglia activation is the major difference between the slow clearance described here, where no perturbation of the immune system is expected, and the rapid clearance described in studies involving antibody or viral injection.']	(45651, 45921)	['CL:0000129', 'GO:0001774', 'GO:0001774', 'GO:0042571', 'NCBITaxon:10239', 'UBERON:0002405', 'UBERON:0002405']
16279840	251	['In isolation, mild activation of microglia by injection damage or opsinization may not be adequate to induce substantial phagocytosis, but when combined with an Aβ-lowering agent, such as neprilysin or Aβ-targeted antibodies, the two may work in concert to clear peptide deposits.']	(45922, 46202)	['CL:0000129', 'GO:0001774', 'GO:0001774', 'GO:0001774', 'GO:0006909', 'GO:0042571', 'PR:000001898']
16279840	252	['Consistent with this hypothesis, strong activation of microglia through transgenic expression of TGFβ [58] or central injection of lipopolysaccharide [59,60] can by itself substantially reduce plaque burden in APP transgenic mice.']	(46203, 46433)	['CHEBI:16412', 'CL:0000129', 'GO:0001774', 'GO:0001774', 'GO:0001774', 'GO:0010467', 'NCBITaxon:10088', 'PR:000000046', 'PR:000004168']
16279840	253	['But in the case of acute antibody- and/or injury-mediated activation, once the inflammation has passed, and the antibody and bound peptide have been cleared and degraded, the remaining Aβ quickly reaggregates and amyloid pathology is reestablished [49].']	(46434, 46687)	['CHEBI:60425', 'GO:0042571', 'GO:0042571']
16279840	254	['This finding reinforces the notion that without continued stimulation, microglia in mouse models do not maintain the same level of sustained activation that may occur in humans.']	(46688, 46865)	['CL:0000129', 'NCBITaxon:10088', 'NCBITaxon:9606']
16279840	255	['SantaCruz et al.']	(46867, 46883)	[]
16279840	256	['recently published a study of mice that express P301L human tau via a similar vector system [61].']	(46884, 46981)	['GO:0010467', 'NCBITaxon:10088', 'NCBITaxon:9606', 'PR:000010173', 'SO:0000440']
16279840	257	['As in our tet-off APP mice, SantaCruz et al.']	(46982, 47026)	['NCBITaxon:10088', 'PR:000004168']
16279840	258	['found that tau neurofibrillary tangles, like amyloid plaques, are not cleared efficiently following transgene suppression.']	(47027, 47149)	['CHEBI:60425', 'GO:0097418', 'GO:0097418', 'GO:0097418', 'PR:000010173', 'SO:0000902']
16279840	259	['The lack of clearance in both models of AD pathology comes as a stark contrast to the rapid removal of protein aggregates found in similar tet-off mouse models of Huntington [32] and prion disease [62].']	(47150, 47352)	['NCBITaxon:10088']
16279840	260	['In these cases, disrupting the input of new monomer to the system via dox-mediated transgene suppression led to relatively rapid clearance of protein aggregates.']	(47353, 47514)	['CHEBI:50845', 'SO:0000902']
16279840	261	['By contrast, our study and that of SantaCruz et al.']	(47515, 47566)	[]
16279840	262	['suggest that protein aggregates in AD may be more tenacious than in other neurodegenerative disorders.']	(47567, 47669)	[]
16279840	263	['Perhaps once aggregated, Aβ and tau are either inherently more stable than other protein aggregates or more resistant to intra- and extracellular clearance mechanisms.']	(47670, 47837)	['GO:0005622', 'GO:0005622', 'GO:0005622', 'GO:0005576', 'PR:000010173']
16279840	264	['One question we were not able to address in this study is whether abrogating synthesis of new Aβ halts the progression of cognitive decline.']	(47839, 47979)	['GO:0034205', 'GO:0034205', 'GO:0034205', 'GO:0050890']
16279840	265	['Studies from the tet-off tau mice suggest that protein clearance may in fact not be required for cognitive improvement following transgene suppression [61].']	(47980, 48136)	['GO:0050890', 'NCBITaxon:10088', 'PR:000010173', 'SO:0000902']
16279840	266	['At present, because of unexpected noncognitive behavioral abnormalities, it is not clear whether the tet-off APP mice can be used to address the same question in the context of amyloid pathology.']	(48137, 48332)	['CHEBI:60425', 'GO:0050890', 'NCBITaxon:10088', 'PR:000004168']
16279840	267	['Both lines of tTA/APP mice we studied here display extreme hyperactivity visible as cage circling and quantified by activity monitoring (see Figure 7).']	(48333, 48484)	['NCBITaxon:10088', 'PR:000004168']
16279840	268	['Many of the double transgenic mice showed similar circular patterns of swimming near the edge of the tank when tested in the Morris water maze.']	(48485, 48628)	['CHEBI:15377', 'GO:0036268', 'NCBITaxon:10088']
16279840	269	['Expression of this phenotype makes standard tests of learning and memory uninterpretable.']	(48629, 48718)	['GO:0007612', 'GO:0007613']
16279840	270	['Hyperactivity nonspecifically inhibits choice-driven changes in movement, the key element behind all cognitive behavioral paradigms.']	(48719, 48851)	['GO:0050890']
16279840	271	['We are currently working to determine whether hyperactivity correlates with expression of the APPswe/ind holoprotein or its proteolytic derivatives.']	(48852, 49000)	['GO:0010467', 'GO:0006508']
16279840	272	['Preliminary studies suggest that hyperactivity does not appear quickly when dox-reared mice are shifted to nonmedicated diets (J. L. J., unpublished data).']	(49001, 49156)	['CHEBI:50845', 'NCBITaxon:10088']
16279840	273	['These data may indicate that the neuroactive culprit is not immediately present after transgenic APP synthesis is initiated, but requires additional time to develop.']	(49157, 49322)	['GO:0042983', 'GO:0042983', 'PR:000004168']
16279840	274	['Alternatively, hyperactivity may be caused by neuronal alterations due to transgene expression during early postnatal development.']	(49323, 49453)	['CL:0000540', 'GO:0010467', 'GO:0007567', 'SO:0000902']
16279840	275	['Further experiments are needed to distinguish between these possibilities.']	(49454, 49528)	[]
16279840	276	['In summary, we demonstrate that abrogating Aβ production halts the progression of pathologic changes in a transgenic mouse model of Alzheimer-type amyloidosis.']	(49530, 49689)	['GO:0034205', 'GO:0034205', 'NCBITaxon:10088']
16279840	277	['However, despite dramatic reductions in Aβ synthesis, neuritic plaques are stable structures in vivo that do not quickly disaggregate.']	(49690, 49824)	['GO:0034205', 'GO:0034205', 'GO:0043005']
16279840	278	['It is possible that a combination of therapies to limit Aβ production, increase Aβ degradation, and enhance phagocytosis of deposited amyloid may be required to reverse damage associated with AD.']	(49825, 50020)	['CHEBI:60425', 'GO:0034205', 'GO:0034205', 'GO:0006909']
16279840	279	['However, if started early enough in the course of disease, secretase inhibitors alone could provide substantial benefit in slowing pathogenic processes linked to amyloid deposition.']	(50021, 50202)	['CHEBI:35222', 'CHEBI:60425']
16279840	280	['Even at later stages in the disease, the presence of substantial microglial activation in human AD [40] suggests that simply slowing the formation of new amyloid deposits may allow ongoing phagocytosis to diminish preexisting lesions.']	(50203, 50437)	['CHEBI:60425', 'CL:0000129', 'GO:0001774', 'GO:0001774', 'GO:0006909', 'NCBITaxon:9606']
16279840	281	['However, the development of safe and effective secretase inhibitors will ultimately be required to determine whether the human brain has the capacity to repair amyloid-associated damage of AD once the progression of pathology is arrested.']	(50438, 50676)	['CHEBI:35222', 'CHEBI:60425', 'NCBITaxon:9606', 'UBERON:0000955']
16279840	282	['Supporting Information\n\nFigure S1\n\nTransgenic APP Expression and Suppression by Dox in the Four New Tet-Off APP Lines\n\nWestern blotting with human-specific antibody 6E10 reveals transgene-derived full-length APP in cortical homogenates from untreated animals (left lanes of each panel).']	(50678, 50964)	['CHEBI:50845', 'GO:0010467', 'GO:0042571', 'NCBITaxon:9606', 'NCBITaxon:33208', 'PR:000004168', 'PR:000004168', 'PR:000004168', 'SO:0000902']
16279840	283	['The new lines produce exceptionally high levels of transgene expression; an equal amount of brain homogenate from a standard transgenic APP line is shown for comparison (extreme left lane, Standard Tg line C3–3; [15,63]).']	(50965, 51186)	['GO:0010467', 'PR:000004168', 'SO:0000902', 'UBERON:0000955']
16279840	284	['After 1 mo of dox treatment, transgenic protein in all four new tet-off APP lines is reduced to residual levels (+ dox; right lanes of each panel).']	(51187, 51334)	['CHEBI:50845', 'CHEBI:50845', 'PR:000004168']
16279840	285	['(474 KB TIF).']	(51336, 51349)	[]
16279840	286	['Click here for additional data file.']	(51351, 51387)	[]
16279840	287	['Figure S2\n\nTransgenic APP mRNA Is Brain-Specific\n\nA slot blot of mRNA harvested from various tissues in three of the four new tet-off APP lines and a nontransgenic control was used to examine transgenic mRNA expression.']	(51389, 51608)	['GO:0010467', 'PR:000004168', 'PR:000004168', 'UBERON:0000955', 'UBERON:0000479']
16279840	288	['Hybridization is seen only in the brain; no signal above background is seen in any other tissue.']	(51609, 51705)	['GO:0097617', 'UBERON:0000955', 'UBERON:0000479']
16279840	289	['(781 KB PSD).']	(51707, 51720)	[]
16279840	290	['Click here for additional data file.']	(51722, 51758)	[]
16279840	291	['Figure S3\n\nAmyloid Pathology in the Cortex Reiterates That in the Hippocampus\n\nAmyloid histology was performed on sections from line 107 double transgenic mice by Hirano silver stain (top row), thioflavin-S (middle row), and Aβ immunohistochemistry (bottom row) to examine the persistence of pathology following transgene suppression.']	(51760, 52094)	['CHEBI:60425', 'CHEBI:60425', 'NCBITaxon:10088', 'SO:0000902', 'UBERON:0001851']
16279840	292	['As in the hippocampus (see Figure 4 and text), the progression of amyloid pathology in the cortex worsens substantially between 6 and 9 mo of age in untreated mice.']	(52095, 52259)	['CHEBI:60425', 'NCBITaxon:10088', 'UBERON:0001851']
16279840	293	['This progression is completely prevented by suppression of the transgene with dox.']	(52260, 52342)	['CHEBI:50845', 'SO:0000902']
16279840	294	['For comparison, normal neurohistology is shown in an age-matched single transgenic (tTA only) animal.']	(52343, 52444)	['NCBITaxon:33208']
16279840	295	['No amyloid pathology has been detected in either APP or tTA single transgenic animals up to 15 mo of age.']	(52445, 52550)	['CHEBI:60425', 'NCBITaxon:33208', 'PR:000004168']
16279840	296	['(4.8 MB PSD).']	(52552, 52565)	[]
16279840	297	['Click here for additional data file.']	(52567, 52603)	[]
16279840	298	['Figure S4\n\nDiffuse Deposits Do Not Disperse During Aβ Suppression\n\nCampbell–Switzer silver stain was used to differentiate cored (brown) from diffuse (black) deposits in line 107 tTA/APP mice.']	(52605, 52797)	['NCBITaxon:10088', 'PR:000004168']
16279840	299	['This stain demonstrates that both types of deposit persist throughout long periods of transgene suppression.']	(52798, 52906)	['SO:0000902']
16279840	300	['The lower panels, showing low-power images (10×) of frontal cortex from each condition, reveal little change in the extent of diffuse amyloid following up to 6 mo of Aβ suppression.']	(52907, 53088)	['CHEBI:60425', 'UBERON:0001870', 'UBERON:0001870']
16279840	301	['High-power images (40×) in the upper panels show that the diffuse halo surrounding individual cored deposits remains relatively unchanged in treated mice.']	(53089, 53243)	['NCBITaxon:10088']
16279840	302	['Untreated tTA single transgenic animals are shown as a negative control.']	(53244, 53316)	['NCBITaxon:33208']
16279840	303	["Protocol for the Campbell-Switzer Alzheimer's Method was kindly shared by Robert Switzer, III (NeuroScience Associates, Knoxville, Tennessee, United States), and can be downloaded at http://www.nsalabs.com/Documents/publications/campbell-switzer_protocol.htm [64,65]."]	(53317, 53584)	[]
16279840	304	['(923 KB JPG).']	(53586, 53599)	[]
16279840	305	['Click here for additional data file.']	(53601, 53637)	[]
16279840	306	['Figure S5\n\nChronic Transgene Suppression and Arrest of Aβ Aggregate Formation in an Independent Line of Tet-Off APP Mice (CaMKIIα-tTA × tet-APPswe/ind Line 18)\n\n(A) The experiment presented in the text for line 107 tet-off APP was repeated with a second tet-off APP line (line 18) to control for integration site artifacts.']	(53639, 53962)	['NCBITaxon:10088', 'PR:000004168', 'PR:000003199', 'PR:000004168', 'PR:000004168', 'SO:0000902', 'SO:0000366', 'SO:0000366']
16279840	307	['Cortical homogenates from untreated control and dox-treated double transgenic mice were immunoblotted for full-length APP with the human-specific antibody 6E10 to confirm transgene suppression at the time of harvest.']	(53963, 54179)	['CHEBI:50845', 'GO:0042571', 'NCBITaxon:10088', 'NCBITaxon:9606', 'PR:000004168', 'SO:0000902', 'UBERON:0001851']
16279840	308	['Immunostaining for endogenous superoxide dismutase (SOD1) was included as a loading control.']	(54180, 54272)	['CHEBI:18421', 'PR:000015399']
16279840	309	['(B) Quantitation of signal intensity from the Western blot in (A) shows transgenic APP levels in line 18 are suppressed by more than 98% following 3 mo of dox treatment (significant effect of group ANOVA F2,8 = 1559.7, p < 0.001).']	(54274, 54504)	['CHEBI:50845', 'PR:000004168']
16279840	310	['This level of suppression was equal to or better than that attained in line 107 (see Figure 3B).']	(54505, 54601)	[]
16279840	311	['(C) Serial dilution filter trap assay was used to quantify aggregated Aβ in cortical homogenates.']	(54603, 54700)	['UBERON:0001851']
16279840	312	['(D) Quantitation of signal intensity in the linear range of the dilution series shown in (C).']	(54702, 54795)	[]
16279840	313	['Consistent with the amyloid histology shown in Figure S5, aggregate formation was significantly increased between 6 and 9 mo of age in untreated mice (significant effect of group ANOVA F2,18 = 12.14, p < 0.001).']	(54796, 55007)	['CHEBI:60425', 'NCBITaxon:10088']
16279840	314	['Aggregate formation was completely arrested by transgene suppression, and is identical in 9-mo-old mice treated with dox for 3 mo as in untreated animals harvested when treatment began (p > 0.5, Tukey post-hoc test).']	(55008, 55224)	['CHEBI:50845', 'NCBITaxon:10088', 'NCBITaxon:33208', 'SO:0000902']
16279840	315	['*, p < 0.05; **, p < 0.005; ***, p < 0.001 versus 9-mo-old untreated mice, Tukey post-hoc test.']	(55225, 55320)	['NCBITaxon:10088']
16279840	316	['(962 KB TIF).']	(55322, 55335)	[]
16279840	317	['Click here for additional data file.']	(55337, 55373)	[]
16279840	318	['Figure S6\n\nArrest of Amyloid Progression by Chronic Transgene Suppression in Line 18 Tet-Off APP Mice\n\nAmyloid histology in cortical (first and third rows) and hippocampal (second and fourth rows) sections from untreated tTA/APP mice shows a dramatic progression of pathology between 6 and 9 mo of age.']	(55375, 55677)	['CHEBI:60425', 'CHEBI:60425', 'NCBITaxon:10088', 'NCBITaxon:10088', 'PR:000004168', 'PR:000004168', 'SO:0000902', 'UBERON:0001851']
16279840	319	['Suppression of transgenic APP expression arrests this progression, although without any sign of plaque clearance (6 mo + 3 mo dox).']	(55678, 55809)	['CHEBI:50845', 'GO:0010467', 'PR:000004168']
16279840	320	['Hirano silver stain (top panels); thioflavin-S (bottom panels).']	(55810, 55873)	[]
16279840	321	['(5.8 MB PSD).']	(55875, 55888)	[]
16279840	322	['Click here for additional data file.']	(55890, 55926)	[]
16279840	323	['Patient Summary\n\nBackground\n\nPatients with Alzheimer disease (AD) have elevated levels of a small protein called amyloid-β peptide that sticks together to form what are known as amyloid plaques in their brains.']	(55928, 56138)	['CHEBI:60425', 'UBERON:0000955']
16279840	324	['This peptide is normally made at low levels in healthy individuals, and is made when a larger protein called amyloid precursor protein (APP) is cut down in size.']	(56139, 56300)	['MOP:0000780', 'NCBITaxon:1', 'PR:000004168', 'PR:000004168', 'PR:000004168', 'PR:000004168']
16279840	325	['New treatments are now being developed that will decrease the amount of Aβ produced from APP.']	(56301, 56394)	['PR:000004168']
16279840	326	['However, it is not clear whether lowering the production of Aβ will allow the brain to heal itself by clearing the amyloid plaques.']	(56395, 56526)	['CHEBI:60425', 'GO:0034205', 'GO:0034205', 'GO:0034205', 'UBERON:0000955']
16279840	327	['The answer to this question may be important for deciding when Aβ-lowering drugs should be started, and may also determine how effective they are in reversing the mental symptoms of AD.']	(56527, 56712)	['CHEBI:23888']
16279840	328	['What Did the Researchers Do and Find?']	(56714, 56751)	[]
16279840	329	['Because new drugs designed to lower Aβ levels are still in development, they are not available for testing in animal models of the disease.']	(56753, 56892)	['CHEBI:23888', 'NCBITaxon:33208']
16279840	330	['Instead, basic questions about the effectiveness of this type of treatment must be answered using systems that mimic how the drugs work.']	(56893, 57029)	['CHEBI:23888']
16279840	331	['To do this, the authors created mice that produce too much APP and that develop the same amyloid lesions as do human patients with AD.']	(57030, 57164)	['CHEBI:60425', 'NCBITaxon:10088', 'NCBITaxon:9606', 'PR:000004168']
16279840	332	['Unlike normal mice, these mice also carried a “switch” gene that allowed the researchers to turn off APP by feeding the mice special food.']	(57165, 57303)	['CHEBI:33290', 'GO:0007631', 'NCBITaxon:10088', 'NCBITaxon:10088', 'NCBITaxon:10088', 'PR:000004168', 'SO:0000704']
16279840	333	['Turning off APP in these mice had the same effect as treating them with Aβ-lowering drugs, and so the researchers were able to ask what happened to the amyloid plaques after Aβ production was shut down.']	(57304, 57506)	['CHEBI:23888', 'CHEBI:60425', 'GO:0034205', 'GO:0034205', 'NCBITaxon:10088', 'PR:000004168']
16279840	334	['They showed that lowering Aβ production prevents the amyloid lesions from getting worse as the disease progresses.']	(57507, 57621)	['CHEBI:60425', 'GO:0034205', 'GO:0034205']
16279840	335	['This means that treatment with Aβ-lowering drugs may be able to stop the disease from filling the brain with plaques.']	(57622, 57739)	['CHEBI:23888', 'UBERON:0000955']
16279840	336	['However, the researchers also found that the amyloid lesions that had formed before treatment was started remained intact throughout the experiment.']	(57740, 57888)	['CHEBI:60425']
16279840	337	['What Do These Findings Mean?']	(57890, 57918)	[]
16279840	338	['These results indicate that treatments designed to lower the production of Aβ may be an important part of future AD treatment, as this approach seems to prevents additional amyloid plaques from forming in the mouse brain.']	(57920, 58141)	['CHEBI:60425', 'GO:0034205', 'GO:0034205', 'GO:0034205', 'NCBITaxon:10088', 'UBERON:0000955']
16279840	339	['However, by itself, this strategy may not be able to rid the brain of plaques that have already formed in the brain before treatment is started.']	(58142, 58286)	['UBERON:0000955', 'UBERON:0000955']
16279840	340	['The findings suggest that early treatment may be important for this approach to succeed.']	(58287, 58375)	[]
16279840	341	['Where Can I Get More Information Online?']	(58377, 58417)	[]
16279840	342	["MedlinePlus has several Web pages of information on Alzheimer disease:\n\nhttp://www.nlm.nih.gov/medlineplus/alzheimersdisease.html\n\nThe ADEAR Center of the US Government's National Institute on Aging also has information on Alzheimer disease:\n\nhttp://www.alzheimers.org/\n\nThe Alzheimer's Association Web site contains information on both caregiving and research:\n\nhttp://www.alz.org\n\nAcknowledgements\n\nWe thank Patrick Tremblay for helpful advice on the tet system at a critical time in the project, and Mark Mayford for sharing the CaMKIIα-tTA mice through Jackson Laboratory."]	(58419, 58995)	['GO:0007568', 'NCBITaxon:10088', 'PR:000003199']
16279840	343	['We also thank Fraser Moss for saving several immunoblots with last-minute shipments, Andy Groves for many thoughtful discussions, Neil Segil for generously sharing his laboratory and equipment, Beth Olson, Natasha Bouey, and Yolanda Jackson for outstanding animal care, Debbie Swing for expert microinjection, and Dave Fromholt for genotyping and dissection.']	(58996, 59354)	['NCBITaxon:33208']
16279840	344	['We gratefully acknowledge Takeda Chemical Industries for providing antibodies BAN50, BA27, and BC05, Konrad Beyreuther and Andreas Weidemann for providing 22C11 antibody, and Ed Koo for sharing CT15 antibody.']	(59355, 59563)	['GO:0042571', 'GO:0042571', 'GO:0042571']
16279840	345	["This work was supported by grants from the Johns Hopkins Alzheimer's Disease Research Center (JLJ), the National Alliance for Research on Schizophrenia and Depression (Young Investigator Award [JLJ]), the Rose Hills Foundation (JLJ), the Alzheimer's Association (Zenith Award [DRB]), the National Institute of Aging (K01 AG26144–01 [JLJ], P50 AGO5146–20 [DRB], R01 AG006656–16 [SGY], and P01 AG015453 [SGY]), the National Institute of Neurologic Disease and Stoke (R01 NS 047225 [DRB]), and the National Cancer Institute (NAJ and NGC)."]	(59564, 60099)	['GO:0007568', 'UBERON:0001016']
16279840	346	['The funding agencies generously provided for research supplies, animal care, and salary support; the funders of this work had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.']	(60100, 60335)	['NCBITaxon:33208']
16279840	347	['Abbreviations\n\nAβ - amyloid-β\n\nAD - Alzheimer disease\n\nAPLP - amyloid precursor–like protein\n\nAPP - amyloid precursor protein\n\nCaMKIIα - calcium-calmodulin kinase IIα\n\ndox - doxycycline\n\nFA - formic acid\n\nGFAP - glial fibrillary acidic protein\n\nmo/huAPP695 - mouse APP with a humanized Aβ domain\n\nPBS - phosphate-buffered saline\n\nSDS - sodium dodecyl sulfate\n\nswe/ind - Swedish/Indiana\n\ntTA - tetracycline transactivator\n\nFigures and Tables\n\nFigure 1\n\nControl of Transgenic APP Expression by Dox\n\n(A) Western blotting for transgenic APP using the human-specific 6E10 antibody shows expression of full-length protein in forebrain tissue from young predeposit double transgenic animals (line 107) and its suppression following dox treatment.']	(60337, 61076)	['CHEBI:50845', 'CHEBI:50845', 'CHEBI:30751', 'CHEBI:30751', 'CHEBI:30751', 'CHEBI:37527', 'CHEBI:8984', 'CHEBI:8984', 'CHEBI:8984', 'CHEBI:8984', 'CHEBI:27902', 'CHEBI:50845', 'CHEBI:50845', 'CL:0000125', 'GO:0010468', 'GO:0010468', 'GO:0010468', 'GO:0010467', 'GO:0042571', 'NCBITaxon:10088', 'NCBITaxon:10088', 'NCBITaxon:9606', 'NCBITaxon:33208', 'PR:000004168', 'PR:000004168', 'PR:000004168', 'PR:000004168', 'PR:000004168', 'PR:000004168', 'PR:000003199', 'PR:000003199', 'PR:000003199', 'PR:000003199', 'PR:000003199', 'PR:000003199', 'PR:000007939', 'PR:000007939', 'PR:000007939', 'PR:000007939', 'PR:000007939', 'PR:000004168', 'PR:000004168', 'PR:000004168', 'SO:0000417', 'UBERON:0001890', 'UBERON:0000479']
16279840	348	['Untreated animals show high levels of transgene expression; protein levels drop dramatically in animals acutely treated with dox for 2 wk.']	(61077, 61215)	['CHEBI:50845', 'GO:0010467', 'NCBITaxon:33208', 'NCBITaxon:33208', 'SO:0000902']
16279840	349	['A faint, but detectable band of full-length protein remains in acutely treated animals that can be eliminated in mice born and raised on dox.']	(61216, 61357)	['CHEBI:50845', 'GO:0007567', 'NCBITaxon:33208', 'NCBITaxon:10088']
16279840	350	['(B) Immunoblotting with the N-terminal antibody 22C11 to detect both transgenic and endogenous protein shows that dox treatment reduces APP/APLP to levels found in nontransgenic mice.']	(61359, 61542)	['CHEBI:50845', 'GO:0042571', 'NCBITaxon:10088', 'PR:000004168']
16279840	351	['(C) Measurement of signal intensity from the Western blot in (A) shows transgenic APP levels are decreased more than 95% by dox in both acutely and chronically treated animals (97.2% for 4 wk + 2 wk dox, 98.0% for reared on dox versus 4 wk untreated; ANOVA effect of treatment group F4,15 = 85.55, p < 0.001).']	(61544, 61853)	['CHEBI:50845', 'CHEBI:50845', 'CHEBI:50845', 'NCBITaxon:33208', 'PR:000004168']
16279840	352	['APP levels in 4 wk + 2 wk dox, reared on dox, and nontransgenic (NTg) were not significantly different (p > 0.9, Tukey post-hoc test).']	(61854, 61988)	['CHEBI:50845', 'CHEBI:50845', 'PR:000004168']
16279840	353	['(D) Measurement of signal intensity from the Western blot in (B) shows total APP/APLP levels in dox-treated tTA/APP mice are significantly lower than in 4-wk-old untreated mice (ANOVA effect of treatment group F4,15 = 84.41, p < 0.001) and indistinguishable from those of nontransgenic animals (p > 0.9, Tukey post-hoc test).']	(61990, 62315)	['CHEBI:50845', 'NCBITaxon:10088', 'NCBITaxon:10088', 'NCBITaxon:33208', 'PR:000004168', 'PR:000004168']
16279840	354	['*, p < 0.001 versus untreated 4-wk-old mice, Tukey post-hoc test applied to significant effect of group ANOVA.']	(62316, 62426)	['NCBITaxon:10088']
16279840	355	['Figure 2\n\nAβ Levels Are Dramatically Reduced by Transgene Suppression\n\nCortical homogenates from young, predeposit tTA/APP mice used for Western blot in Figure 1 (line 107) were fractionated by sequential multi-step extraction with PBS, 2% SDS, and 70% FA followed by human-specific Aβ ELISA to measure transgene-derived peptide in each fraction.']	(62428, 62774)	['CHEBI:8984', 'CHEBI:30751', 'NCBITaxon:10088', 'NCBITaxon:9606', 'PR:000004168', 'SO:0000902', 'SO:0000902', 'UBERON:0001851']
16279840	356	['Aβ40 is shown in white, Aβ42 in black.']	(62775, 62813)	[]
16279840	357	['(A) PBS-soluble Aβ levels are substantially reduced by both acute and chronic dox treatment (ANOVA, effect of treatment group F4,24 = 137.10 and 386.01, p < 0.001, for Aβ40 and Aβ42, respectively).']	(62815, 63012)	['CHEBI:50845']
16279840	358	['Aβ levels in treated animals are indistinguishable from nontransgenic (NTg) animals (p > 0.3, Tukey post-hoc test).']	(63013, 63128)	['NCBITaxon:33208', 'NCBITaxon:33208']
16279840	359	['(B) In the young animals tested here prior to the formation of visible amyloid deposits, most Aβ is extracted into the SDS fraction (84% and 76% of all transgene-derived Aβ40 and Aβ42, respectively).']	(63130, 63329)	['CHEBI:60425', 'CHEBI:8984', 'NCBITaxon:33208', 'SO:0000902']
16279840	360	['As in the PBS-soluble fraction, Aβ levels in the SDS fraction are significantly lowered by dox treatment compared to untreated animals (ANOVA effect of group F4,24 = 197.57 and 163.48, p < 0.001, for Aβ40 and Aβ42, respectively).']	(63330, 63559)	['CHEBI:8984', 'CHEBI:50845', 'NCBITaxon:33208']
16279840	361	['Acutely treated animals retained a small (although significant) amount of residual peptide (p < 0.001 compared to nontransgeinc, Tukey post-hoc test), whereas Aβ levels in mice born and raised on dox were reduced to levels indistinguishable from nontransgenic (p > 0.8, Tukey post-hoc test).']	(63560, 63851)	['CHEBI:50845', 'GO:0007567', 'NCBITaxon:33208', 'NCBITaxon:10088']
16279840	362	['(C) The FA-soluble fraction already contains a small but significant pool of aggregated Aβ42 in untreated animals by 4 wk of age (p < 0.05 versus nontransgenic; Tukey post-hoc test applied to significant effect of group ANOVA F4,24 = 17.11, p < 0.001).']	(63853, 64105)	['CHEBI:30751', 'NCBITaxon:33208']
16279840	363	['By 6 wk of age, the amount of Aβ in the FA fraction is increased significantly preceding the appearance of visible deposits 2 wk later.']	(64106, 64241)	['CHEBI:30751']
16279840	364	['The FA pool is the only peptide fraction not lowered by acute dox treatment (4 wk untreated = 4 wk + 2 wk dox, p > 0.9, Tukey post-hoc test), consistent with poor turnover of aggregated Aβ species.']	(64242, 64439)	['CHEBI:30751', 'CHEBI:50845', 'CHEBI:50845']
16279840	365	['(D) Measurements of total Aβ, including both endogenous and transgene-derived peptides, show that animals born and raised on dox harbor Aβ levels identical to nontransgenic animals (p > 0.9, Tukey post-hoc test, effect of group ANOVA F4,24 = 39.13 and 35.29, p < 0.001, for Aβ40 and Aβ42, respectively).']	(64441, 64744)	['CHEBI:50845', 'GO:0007567', 'NCBITaxon:33208', 'NCBITaxon:33208', 'SO:0000902']
16279840	366	['Whereas chronic transgene suppression fully prevents synthesis of both peptides, acute dox treatment fully suppresses Aβ40 levels (p > 0.8, Tukey post-hoc test), but leaves a small amount of nonsuppressed Aβ42.']	(64745, 64955)	['CHEBI:50845', 'GO:0043043', 'GO:0043043', 'GO:0043043', 'SO:0000902']
16279840	367	['The residual Aβ42 observed in acutely treated young animals derives from uncleared aggregates extracted in the SDS and FA fractions.']	(64956, 65088)	['CHEBI:8984', 'CHEBI:30751', 'NCBITaxon:33208']
16279840	368	['*, p < 0.05; **, p < 0.005; ***, p < 0.001 versus 4-wk-old untreated mice, Tukey post-hoc applied to significant effect of group ANOVA.']	(65089, 65224)	['NCBITaxon:10088']
16279840	369	['Figure 3\n\nRobust Transgene Suppression in Older Mice with Preexisting Amyloid Pathology\n\n(A) Cortical homogenates from 6- to 12-mo-old animals used for pathology studies described below (line 107) were immunoblotted with human-specific antibody 6E10 to examine transgene suppression following 3 or 6 mo of dox treatment.']	(65226, 65546)	['CHEBI:60425', 'CHEBI:50845', 'GO:0042571', 'NCBITaxon:10088', 'NCBITaxon:33208', 'NCBITaxon:9606', 'SO:0000902', 'SO:0000902', 'UBERON:0001851']
16279840	370	['The blot was co-immunostained for endogenous superoxide dismutase 1 (SOD1) as a control for loading.']	(65547, 65647)	['CHEBI:18421', 'PR:000015399', 'PR:000015399', 'PR:000015399', 'PR:000015399']
16279840	371	['(B) Quantitation of signal intensity from the Western blot shown in (A).']	(65649, 65721)	[]
16279840	372	['Transgenic APP levels are significantly suppressed following 3 or 6 mo of dox treatment (96.9% and 97.6%, respectively).']	(65722, 65842)	['CHEBI:50845', 'PR:000004168']
16279840	373	['*, p < 0.001 compared to 6-mo-old untreated animals, Tukey post-hoc test applied to significant effect of group ANOVA F3,12 = 107.22, p < 0.001.']	(65843, 65987)	['NCBITaxon:33208']
16279840	374	['These data demonstrate that strong transgene suppression is attained both before and after the onset of amyloid pathology (see Figure 1 for predeposit experiments).']	(65988, 66152)	['CHEBI:60425', 'SO:0000902']
16279840	375	['(C) Experimental design.']	(66154, 66178)	[]
16279840	376	['To examine the effects of chronic Aβ suppression on amyloid pathology after the onset of deposition, we compared untreated controls harvested at 6 and 9 mo of age to animals placed on dox at 6 mo of age and harvested after 3 or 6 mo of treatment.']	(66179, 66425)	['CHEBI:60425', 'CHEBI:50845', 'NCBITaxon:33208']
16279840	377	['(D) Dox treatment leads to rapid transgene suppression even in 6-mo-old tTA/APP mice.']	(66427, 66512)	['CHEBI:50845', 'NCBITaxon:10088', 'PR:000004168', 'SO:0000902']
16279840	378	['Immunostaining with 6E10 shows APPswe/ind levels are dramatically reduced in 6-mo-old mice treated for 1 wk with dox (upper panel).']	(66513, 66644)	['CHEBI:50845', 'NCBITaxon:10088']
16279840	379	['A separate blot was immunostained for APP C-terminal fragments with CT15 antibody to show that the precursors to Aβ cleavage are decreased in parallel with the full-length protein (middle panel).']	(66645, 66840)	['GO:0042571', 'MOP:0000780', 'PR:000004168']
16279840	380	['Costaining for superoxide dismutase 1 was used as an internal control for loading (lower panel, taken from bottom half of 6E10 blot).']	(66841, 66974)	['CHEBI:18421', 'PR:000015399', 'PR:000015399', 'PR:000015399']
16279840	381	['Figure 4\n\nSuppression of Transgenic APP Arrests Progression of Amyloid Pathology\n\n(A) Aggregated Aβ was quantified in cortical tissue from dox-treated and control tTA/APP mice (line 107) using a filter trap assay.']	(66976, 67189)	['CHEBI:60425', 'CHEBI:50845', 'NCBITaxon:10088', 'PR:000004168', 'PR:000004168', 'UBERON:0001851', 'UBERON:0000479']
16279840	382	['Serial dilutions of protein homogenate were passed through a cellulose acetate filter; protein aggregates larger than the pore size were trapped and immunostained for Aβ.']	(67190, 67360)	[]
16279840	383	['(B) Quantitation of signal intensity in the linear range of each filter trap dilution series (arrow in [A]) was used to compare aggregate load across treatment groups.']	(67362, 67529)	[]
16279840	384	['Aggregated Aβ increased significantly between 6 and 9 mo of age in untreated mice (significant effect of group ANOVA F3,18 = 7.85, p < 0.002).']	(67530, 67672)	['NCBITaxon:10088']
16279840	385	['This progression of pathology was completely prevented by transgene suppression.']	(67673, 67753)	['SO:0000902']
16279840	386	['The amount of aggregated Aβ was identical in untreated mice at 6 mo of age to that in 9- or 12-mo-old animals treated with dox (p > 0.9, Tukey post-hoc test).']	(67754, 67912)	['CHEBI:50845', 'NCBITaxon:10088', 'NCBITaxon:33208']
16279840	387	['Single transgenic tTA samples were included as negative controls and showed no signal above background.']	(67913, 68016)	[]
16279840	388	["*, p < 0.01; **, p < 0.005 versus 9-mo-old untreated mice, Tukey post-hoc test; ***, p < 0.001 versus 9-mo-old untreated mice, Student's t-test."]	(68017, 68161)	['NCBITaxon:10088', 'NCBITaxon:10088']
16279840	389	['(C) Amyloid pathology in the hippocampus of representative mice from each treatment group: Hirano silver stain (top row), thioflavin-S (middle row), and Aβ immunohistochemistry (bottom row).']	(68163, 68353)	['CHEBI:60425', 'NCBITaxon:10088']
16279840	390	['Amyloid burden increases dramatically between 6 and 9 mo of age in untreated animals, but remains stable in transgene-suppressed mice over the same period (6 mo + 3 mo dox and 6 mo + 6 mo dox).']	(68354, 68547)	['CHEBI:60425', 'CHEBI:50845', 'CHEBI:50845', 'NCBITaxon:33208', 'NCBITaxon:10088', 'SO:0000902']
16279840	391	['Single transgenic animals (tTA only shown here) show no sign of amyloid pathology at any age tested.']	(68548, 68648)	['CHEBI:60425', 'NCBITaxon:33208']
16279840	392	['Figure 5\n\nAβ ELISA Confirms Arrest of Progression without Clearance of Peptide in Mice with Preexisting Aggregates\n\nAβ levels in untreated 6- and 9-mo-old tTA/APP line 107 mice (shown in Figure 4) were compared to those in 9- and 12-mo-old animals treated with dox from the age of 6 mo.']	(68650, 68936)	['CHEBI:50845', 'NCBITaxon:10088', 'NCBITaxon:10088', 'NCBITaxon:33208', 'PR:000004168']
16279840	393	['Single transgenic APP samples were included as negative controls.']	(68937, 69002)	['PR:000004168']
16279840	394	['Cortical homogenates were fractionated by sequential multi-step extraction with PBS, 2% SDS, and 70% FA followed by human-specific Aβ ELISA to measure transgene-derived peptide in each fraction.']	(69003, 69197)	['CHEBI:8984', 'CHEBI:30751', 'NCBITaxon:9606', 'SO:0000902', 'UBERON:0001851']
16279840	395	['Aβ40 is shown in white, Aβ42 in black.']	(69198, 69236)	[]
16279840	396	['(A and B) Most Aβ in the brains of plaque-bearing mice is extracted into the FA and SDS fractions.']	(69238, 69336)	['CHEBI:30751', 'CHEBI:8984', 'NCBITaxon:10088', 'UBERON:0000955']
16279840	397	['Consistent with amyloid burden (Figures 4 and Figure S3), SDS- and FA-extracted Aβ levels in untreated 9-mo-old mice were significantly higher than in untreated 6-mo-old mice (Tukey post-hoc test applied to significant effect of group ANOVA for SDS and FA fractions F3,18 = 4.72–12.92, p < 0.02).']	(69337, 69633)	['CHEBI:60425', 'CHEBI:8984', 'CHEBI:30751', 'CHEBI:8984', 'CHEBI:30751', 'NCBITaxon:10088', 'NCBITaxon:10088']
16279840	398	['In contrast, 3 or 6 mo of transgene suppression held Aβ at levels equivalent to those harbored when treatment was started (p > 0.2 compared to 6 mo untreated mice, Tukey post-hoc test).']	(69634, 69819)	['NCBITaxon:10088', 'SO:0000902']
16279840	399	['*, p < 0.05; **, p < 0.005; ***, p < 0.001 versus 9-mo-old untreated mice, Tukey post-hoc test.']	(69820, 69915)	['NCBITaxon:10088']
16279840	400	["Significance for APP versus 9-mo-old untreated mice is based on Student's t-test."]	(69916, 69997)	['NCBITaxon:10088', 'PR:000004168']
16279840	401	['(C) The PBS fraction represents less than 0.1% of total Aβ (note the change in y-axis from [A] and [B]), but only here do Aβ levels in the dox-treated mice differ from those in younger untreated mice.']	(69999, 70199)	['CHEBI:50845', 'NCBITaxon:10088', 'NCBITaxon:10088']
16279840	402	['Although both peptides appear elevated in the treated groups compared to the untreated 6-mo-old mice, only Aβ40 reaches statistical significance (p < 0.05, Tukey post-hoc test applied to significant effect of group ANOVA for Aβ40 F3,18 = 4.60, p < 0.02).']	(70200, 70454)	['NCBITaxon:10088']
16279840	403	['A similar trend was seen for Aβ42, where ANOVA yielded a significant effect of group for PBS-soluble Aβ42 (F3,18 = 3.75, p < 0.03), however this was due only to differences between the untreated 6- and 9-mo-old groups.']	(70455, 70673)	[]
16279840	404	["•, p < 0.05 versus 6-mo-old untreated mice, Tukey post-hoc test; •••, p < 0.001 versus 6-mo-old untreated mice, Student's t-test."]	(70674, 70803)	['NCBITaxon:10088', 'NCBITaxon:10088']
16279840	405	['Figure 6\n\nNeuritic and Glial Pathology Are Unchanged following Transgene Suppression\n\nDystrophic neurites and activated astrocytes surround most compact plaques in tet-off APP mice (line 107).']	(70805, 70997)	['CL:0000125', 'CL:0002627', 'CL:0002627', 'GO:0043005', 'GO:0043005', 'NCBITaxon:10088', 'PR:000004168', 'SO:0000902']
16279840	406	['Dark-stained, ubiquitin-filled neurites and reactive astrocytes form a halo around cored, fibrillar deposits by 6 mo of age that worsens with time in untreated mice.']	(70998, 71163)	['CL:0000127', 'GO:0043005', 'NCBITaxon:10088']
16279840	407	['Both plaque-associated pathologies are arrested, although not reversed, by transgene suppression.']	(71164, 71261)	['SO:0000902']
16279840	408	['Hirano silver stain (top row); GFAP immunohistochemistry (middle row); ubiquitin immunohistochemistry (bottom row).']	(71262, 71377)	['PR:000007939']
16279840	409	['Figure 7\n\nTransgene Suppression Attenuates Hyperactivity in tTA/APP Mice\n\n(A) A 48-h measure of ambulation records extreme hyperactivity in untreated double transgenic mice compared to single transgenic and nontransgenic controls (line 107).']	(71379, 71620)	['GO:0040011', 'NCBITaxon:10088', 'NCBITaxon:10088', 'PR:000004168', 'SO:0000902']
16279840	410	['This phenotype is completely eliminated by rearing the double transgenic mice on dox.']	(71621, 71706)	['CHEBI:50845', 'NCBITaxon:10088']
16279840	411	['(B) The same data shown in (A) are replotted to magnify data from untreated control and dox-treated groups.']	(71708, 71815)	['CHEBI:50845']
16279840	412	['(C and D) Activity levels in the combined control groups of (A) and (B) are here separated by genotype.']	(71817, 71920)	[]
16279840	413	['None of the single transgenic or nontransgenic control groups display the hyperactivity present in untreated tTA/APP animals.']	(71921, 72046)	['NCBITaxon:33208', 'PR:000004168']
16279840	414	['Again, note the y-axes have been enlarged for detail compared to (A).']	(72047, 72116)	[]
16279840	415	['Footnotes\n\nCitation: Jankowsky JL, Slunt HH, Gonzales V, Savonenko AV, Wen JC, et al.']	(72118, 72203)	[]
16279840	416	['(2005) Persistent amyloidosis following suppression of Aβ production in a transgenic model of Alzheimer disease.']	(72204, 72316)	['GO:0034205', 'GO:0034205']
16279840	417	['PLoS Med 2(12): e355.']	(72317, 72338)	[]
